Document:

License Agreement

 Exhibit 10.2 
 CERTAIN MATERIAL HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 LICENSE AGREEMENT 
 This
License Agreement, made and entered into as of the 1st day of December, 2008, is by and between: 
 SOLVAY SA, a Belgian
corporation having its registered office at 33 rue du Prince Albert, B-1050 Brussels, Belgium, acting for itself and on behalf of its Affiliates (as hereinafter defined), hereinafter collectively referred to as “Solvay,” 

and 
 CADENCE PHARMACEUTICALS, INC., a Delaware
corporation having a place of business at 12481 High Bluff Drive, Suite 200, San Diego, California, 92130, United States of America, hereinafter referred to as “Cadence.” 
 Cadence and Solvay are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 RECITALS: 
 A.
Cadence holds a license for the production and commercialization in Europe and North America of omiganan pentahydrochloride for certain indications, including (i) the topical administration to a burn site or a surgical wound site for the
treatment or prevention in humans of burn-related or surgery-related infections; and (ii) the topical administration to a device or the site around the device for the treatment or prevention in humans of device-related infections, including
local catheter site infection and catheter related blood stream infection, under a certain Collaboration and License Agreement between Cadence and Migenix, Inc., dated as of July 30, 2004, as amended on October 6, 2006, and on
April 7, 2008 (the “Cadence-Migenix Agreement”). 
 B. Solvay has performed certain development activities with respect
to omiganan pentahydrochloride, and has in particular been working to develop a commercial process for the production of the same. 
 C. The
Parties signed on December 21, 2007 a Letter of Intent (the “Letter of Intent”) to outline certain terms and conditions of a proposed agreement under which Solvay would perform certain further development studies on omiganan
pentahydrochloride, and further develop a commercial process for the production of the same, and would supply commercial quantities of omiganan pentahydrochloride to Cadence. 
 D. On the date of this Agreement, the Parties entered into a Long-Term Supply Agreement for the validation of Solvay’s production process of
omiganan pentahydrochloride, and the supply by Solvay to Cadence, and the purchase by Cadence from Solvay, of omiganan pentahydrochloride. 
 E. Solvay is willing to grant to Cadence the right to grant a sublicense under Solvay’s relevant patent rights and know-how to a secondary source for the bulk supply of omiganan pentahydrochloride to Cadence, on the terms and
conditions set forth herein. 
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment
has been requested with respect to the omitted portions. 

 NOW THEREFORE, in consideration of the foregoing and the mutual promises contained herein, the Parties
agree as follows: 
  

	1.	CLAUSE 1 – DEFINITIONS 

 1.1 In this Agreement,
the following capitalized terms shall have the following meanings: 
 (a) “Affiliates” shall have the same meaning as in the
Supply Agreement. 
 (b) “Aggregate Annual Requirement” shall have the same meaning as in the Supply Agreement. 

(c) “Binding Requirement” shall have the same meaning as in the Supply Agreement. 
 (d) “Bulk Drug Substance” shall have the same meaning as in the Supply Agreement. 
 (e) “Cadence Confidential Information” shall mean any non-public information in whatever form, disclosed directly or indirectly by
Cadence under the present Agreement, the Confidentiality Agreement or the Supply Agreement. For clarity, “Cadence Confidential Information” may include information of Migenix or other third parties that is disclosed by Cadence to Solvay.

 (f) “Cadence-Migenix Agreement” shall have the same meaning as in the recitals of this Agreement. 
 (g) “Confidential Information” shall mean any non-public information in whatever form, disclosed directly or indirectly by one Party to
the other Party under the present Agreement, the Confidentiality Agreement or the Supply Agreement. For clarity, “Confidential Information” of a Party may include information of third parties that is disclosed by one Party to the other
Party. 
 (h) “Confidentiality Agreement” shall have the same meaning as in the Supply Agreement. 
 (i) “Date of this Agreement” shall mean the first date hereabove written. 
 (j) “Field” shall have the same meaning as in the Supply Agreement. 
 (k) “First Supply Date” shall mean the date notified to Solvay pursuant to the provisions of Sub-Clause 4.2(c). 
 (l) “Improvements” shall have the same meaning as in the Supply Agreement. 
 (m) “Improvement Period” shall mean the period starting on the Secondary Source Effective Date, and ending on the earlier of
(i) #####, (ii) #####, or (iii) #####. 
 (n) “Licensed Process” shall have the same meaning as in the Supply
Agreement. 
 (o) “Omiganan Drug Substance” shall mean any bulk peptide product that contains omiganan pentahydrochloride.

 (p) “Production Capacity” shall have the same meaning as in the Supply Agreement. 
 (q) “Program Commencement Date” shall have the same meaning as in the Supply Agreement. 
 (r) “Requirements Forecast(s)” shall have the same meaning as in the Supply Agreement. 
 (s) “Royalty Bulk Drug Substance” shall have the meaning set forth in Sub-Clause 6.2(b). 
 (t) “Secondary Source” shall have the meaning set forth in Sub-Clause 2.2(a). 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (u) “Secondary Source Effective Date” shall have the meaning set forth in Sub-Clause
2.2(b). 
 (v) “Secondary Source Improvements” shall mean #####. 
 (w) “Solvay Bulk Drug Substance Price” shall mean the applicable price for the equivalent quantity of Bulk Drug Substance set forth in
Appendix A of the Supply Agreement. 
 (x) “Solvay Confidential Information” shall mean any non-public information in
whatever form, disclosed directly or indirectly by Solvay under the present Agreement, the Supply Agreement or the Confidentiality Agreement. For the sake of clarity, “Solvay Confidential Information” may include non-public information of
third parties Solvay has the right to disclose, which is disclosed by Solvay to Cadence or the Secondary Source. 
 (y) “Solvay
Improvements” shall have the same meaning as in the Supply Agreement. 
 (z) “Solvay Know-How” shall have the same
meaning as in the Supply Agreement. 
 (aa) “Solvay Patents” shall have the same meaning as in the Supply Agreement.

 (bb) “Solvay Technology” shall have the same meaning as in the Supply Agreement. 
 (cc) “Specification” shall have the same meaning as in the Supply Agreement. 
 (dd) “Sublicensee” shall have the same meaning as in the Supply Agreement. 
 (ee) “Supply Agreement” shall mean the Long-Term Supply Agreement entered into by and between the Parties of even date herewith, and any
further written agreement between the Parties relating to the supply by Solvay to Cadence, and the purchase by Cadence from Solvay, of Bulk Drug Substance. 
 (ff) “Territory” shall have the same meaning as in the Supply Agreement. 
 (gg)
“Valid Claim” shall have the same meaning as in the Supply Agreement. 
 1.2 Unless otherwise indicated,
“year” shall mean a calendar year, and “quarter” shall mean a three-consecutive calendar month period ending on either March 31, June 30, September 30 or December 31. Except where the
context requires otherwise, the following shall apply with respect to this Agreement: (A) the use of the singular shall be deemed to include the plural, and vice versa; (B) the use of words denoting any gender shall be deemed to include
the other gender; (C) the word “or” shall be construed in the inclusive sense typically associated with the phrase “and/or”; (D) the words “include,” includes” and “including” shall be deemed to
be followed by the phrase “without limitation” and shall not be construed to limit any preceding general statement to the specific or similar items or matters immediately following; (E) any definition of, or reference to, any
agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein); (F) references to any person or entity shall be construed to include such person’s or entity’s successors, heirs and assigns; (G) the words “herein,” “hereof” and
“hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof; (H) all references herein to Articles, Clauses, Exhibits or Schedules shall be
construed to be references to Articles, Clauses, Exhibits or Schedules of this Agreement (unless otherwise stated), and references to this Agreement include all Exhibits and Schedules hereto; and (I) references to any law or regulation, or any
article, section or other division thereof, shall be deemed at all times to include then-current amendments or modifications thereto or any replacement or successor to such law or regulation. 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

	2.	CLAUSE 2 – SUPPLY OF BULK DRUG SUBSTANCE AND DEFINITION OF A SECONDARY SOURCE 

  

	 	2.1	Supply of Bulk Drug Substance 

 (a) The Parties
acknowledge that they have entered into the Supply Agreement, pursuant to which Solvay agrees to supply to Cadence, and Cadence agrees to purchase from Solvay, Bulk Drug Substance pursuant to the terms and conditions set forth therein. 

(b) The Parties agree that, in consideration for the development of the Licensed Process, the associated expenses borne, and investments made by
Solvay, Cadence recognizes Solvay as its primary supplier for Bulk Drug Substance and, except as otherwise provided in Section 5.1 of the Supply Agreement or in Clause 9.3(d) of this Agreement, Cadence shall order from Solvay a minimum of #####
(#####) of the Aggregate Annual Requirement. For the avoidance of doubt, the Parties hereto agree that nothing in this Agreement or in the Supply Agreement is intended to limit or restrict, in any manner, the rights of Cadence, its Affiliates and
Sublicensees, to make, have made, purchase, use, import, export, market or sell any quantity of Omiganan Drug Substance that is made by any means other than by the Licensed Process. 
  

	 	2.2	Secondary Source for Bulk Drug Substance 

 (a)
Selection of a Secondary Source 
 Cadence shall have the right to establish a sole (except as provided under
Sub-Clause 2.2(e)) secondary source for the production of Bulk Drug Substance through the Licensed Process, and supply of the same to Cadence, its Affiliates and Sublicensees, as set forth under this Sub-Clause 2.2(a) (the “Secondary
Source”). 
 Cadence shall notify Solvay in writing of its decision to have such a Secondary Source, and of the
identity of the Secondary Source it has selected. 
 Within five (5) business days from Solvay’s receipt of such
notification, Solvay shall inform Cadence in writing whether the selected Secondary Source is, or is not, acceptable to Solvay. ##### 
 Solvay’s acceptance of a Secondary Source shall not be unreasonably withheld #####. 
 If
Solvay declines to accept any Secondary Source proposed by Cadence, and the Parties are unable to resolve the matter among themselves within five (5) business days, the Parties agree to utilize the arbitration procedure set forth in Sub-Clause
10.2; provided, however, that (a) both Parties agree to use their best efforts to ensure that the arbitration proceeding is completed and a decision rendered within sixty (60) days after the date on which either Party notifies the
other that it wishes to commence an arbitration proceeding; and (b) the prevailing Party in such arbitration shall be entitled 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 
to receive prompt reimbursement from the other Party for any costs it has incurred associated with such arbitration, including administrative and
arbitrators’ fees, but excluding such Party’s own costs and attorneys’ and witness’ fees. 
 (b) Secondary Source
Effective Date 
 The date on which Cadence enters into a definitive written supply agreement with the Secondary Source
for the commercial supply of Bulk Drug Substance, or drug product containing the Bulk Drug Substance produced by the Secondary Source, whether in finished, partially finished or bulk form, shall be the “Secondary Source Effective
Date.” 
 Promptly after the Secondary Source Effective Date, Cadence shall notify Solvay in writing of the Secondary
Source Effective Date. 
 (c) Commencement of the Secondary Source 
 The Parties agree that, except as permitted under Sub-clause 2.2(d), below: 
 (i) the transfer of Solvay Know-How to the Secondary Source according the provisions of Sub-Clause 4.1 shall not commence prior to #####; and 

(ii) Cadence shall not commence purchasing any Bulk Drug Substance from the Secondary Source until #####. 
 (d) Earlier Commencement of the Secondary Source 
 Notwithstanding the provisions of Sub-Clause 2.2(c), the transfer of Solvay Know How to the Secondary Source shall, and the purchase of Bulk Drug Substance by Cadence from the Secondary Source may, commence earlier in
the event that: 
 (i) #####; or 
 (ii) #####; or 
 (iii) #####; or 
 (iv) Solvay is in breach of this Agreement or the Supply Agreement and fails to remedy any such breach as set forth in the applicable agreement. 
 For the avoidance of any doubt, the occurrence of any of the foregoing events (i) to (iv) under this Sub-Clause 2.2(d) shall not release Cadence
from its purchase commitment to Solvay as set forth under Sub-Clause 2.1. 
 (e) New Secondary Source 
 The Parties agree that in case Solvay and the Secondary Source together can’t meet the Binding Requirements, Cadence may engage
another secondary source either in replacement of, or in addition to, the initial Secondary Source, provided such secondary source is accepted by Solvay pursuant to Sub-Clause 2.2(a). For such purpose, the Parties shall negotiate in good faith the
terms and conditions for the establishment of such new secondary source, and amend this Agreement accordingly. 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (f) For the avoidance of doubt, nothing in this Agreement shall be construed to limit Cadence’s
right to engage any third party to ship or store Bulk Drug Substance, to manufacture, ship or store finished pharmaceutical products made from Bulk Drug Substance, or to further process the Bulk Drug Substance. 
  

	3.	CLAUSE 3 – GRANT OF RIGHTS 

  

	 	3.1	Right to Grant Sublicense to the Secondary Source 

 Upon the Program Commencement Date, Solvay shall grant to Cadence a non-exclusive and non-transferable (except as provided under Sub-Clause 10.3) right to grant to the Secondary Source a sole (except as provided under
Sub-Clause 2.2(e)), worldwide and non-transferable sublicense, without right to grant further sublicenses, under: 
 (a) the Solvay Patents,
and the Solvay Know How, existing on the Secondary Source Effective Date, and any patents (including inventor’s certificates), applications, substitutions, extensions, reissues, re-examinations, renewals, divisions, continuations or
continuations-in-part derived from such Solvay Patents or which claim such Solvay Know-How, whenever issued, and 
 (b) any Solvay Improvement
existing on the Secondary Source Effective Date, 
 for the sole purpose of manufacturing, producing and supplying, and performing development
activities related thereto, to Cadence and to any Cadence Affiliate or Sublicensee, the Bulk Drug Substance, and/or drug product containing, or made using, the Bulk Drug Substance, whether in finished, partially finished or bulk form. 
  

	 	3.2	Non-assertion 

 Solvay shall not
assert any Solvay Patent against Cadence, any Cadence Affiliate or Sublicensee, in connection with: 
 (a) researching, developing, using,
importing and exporting Bulk Drug Substance produced under the sublicense granted by Cadence according to the provisions of Sub-Clause 3.1, 
 (b) selling and offering for sale Bulk Drug Substance produced under such sublicense, to Cadence, Cadence’s Affiliates and Sublicensees, and 
 (c) using Bulk Drug Substance produced under such sublicense to manufacture, have manufactured, produce, have produced, research, develop, use, sell, offer for sale, import, export and otherwise commercially exploit
drug product containing, or made using, Bulk Drug Substance produced according to the provisions of Sub-Clause 3.1, whether in finished, partially finished or bulk form. 
  

	 	3.3	Other rights 

 No rights other than
those expressly provided in this License Agreement and under the Supply Agreement are granted by either Party by implication or otherwise. 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	4.	CLAUSE 4 – TRANSFER OF TECHNOLOGY AND TECHNICAL ASSISTANCE SERVICES 

  

	 	4.1	Transfer of Solvay Know-How to the Secondary Source 

 Promptly after the Secondary Source Effective Date (subject to the provisions of Sub-Clause 2.2(c)(i)), Solvay shall provide the Secondary Source with the documents listed in Exhibit B. 
 The Parties agree that, in order to ensure that the attributes of the Bulk Drug Substance from Solvay and the Secondary Source remain
equivalent, such additional documents (in particular, substantive updates to the documents listed in Exhibit B) shall be provided to the Secondary Source by Solvay in a timely manner during the Improvement Period. For the sake of clarity, this
provision shall not be construed to require Solvay to disclose or license Solvay Improvements to the Secondary Source in the event that Solvay is released from its obligations under Sub-Clause 5.1 in accordance with the provisions of Sub-Clause
5.2(b) or 5.2(c). 
  

	 	4.2	Technical assistance services 

 (a) Upon the request
of Cadence or the Secondary Source made after the Program Commencement Date and reasonable prior notice, and subject to the availability of Solvay’s specialized personnel, Solvay shall provide technical assistance services for the disclosure to
the Secondary Source of any element of Solvay Know-How required for the exploitation of the sublicense granted under Sub-Clause 3.1 that is not contained in the documents provided under Sub-Clause 4.1, up to ##### (#####) personnel days excluding
traveling days of Solvay’s personnel. 
 (b) For up to ##### after the Secondary Source Effective Date, upon request of Cadence or the
Secondary Source and reasonable prior notice, and subject to the availability of Solvay’s specialized personnel, Solvay shall continue to provide such technical assistance and access to information, as may be useful to the Secondary Source to
exploit the sublicense granted under Sub-Clause 3.1, up to ##### (#####) personnel days per year excluding traveling days of Solvay’s personnel. 
 (c) The date of release by Cadence, or any of its Affiliates, or Sublicensees, for commercial distribution of the first batch of Bulk Drug Substance manufactured by the Secondary Source shall be the “First
Supply Date.” Promptly after the First Supply Date, Cadence shall notify Solvay in writing of the First Supply Date. 
  

	 	4.3	Language and confidentiality 

 The
disclosures under Sub-Clause 4.1 shall be made, and the technical assistance services under Sub-Clause 4.2 shall be provided, in the English language. 
 Any disclosure, and provision of technical assistance services, hereunder to the Secondary Source shall be made subject to reasonable and customary obligations of confidentiality with respect to non-public Solvay
Know-How no less stringent than the confidentiality obligations of the Parties under Clause 7. 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

	5.	CLAUSE 5 – IMPROVEMENTS 

  

	 	5.1	Solvay Improvements 

 (a) Solvay shall promptly
disclose to the Secondary Source all Solvay Improvements made, developed, or acquired, during the Improvement Period, in writing and in reasonable detail. 
 (b) Solvay shall extend, without any further consideration, the rights and the sublicense granted under Sub-Clauses 3.1 and 3.2, to include all Solvay Improvements disclosed by Solvay pursuant to Sub-Clause 5.1(a),
except as limited under Sub-Clause 5.2(b) or 5.2(c). 
  

	 	5.2	Secondary Source Improvements 

 (a) Cadence shall
require, as a condition of any sublicense granted by Cadence pursuant to Sub-Clause 3.1, that the Secondary Source: 
 (i) promptly disclose
to Solvay all Secondary Source Improvements made, developed, or acquired, during the Improvement Period, in writing and in reasonable detail; 
 (ii) agree to grant to Solvay a royalty-free, worldwide, non-exclusive and non-transferable (except as provided under Sub-Clause 10.3) license, under any Secondary Source Improvement disclosed pursuant to Sub-Clause 5.2(a)(i), without right
to grant sublicenses, for the sole purpose of manufacturing, producing and supplying Bulk Drug Substance and/or Drug Product, whether in finished, partially finished or bulk form, to Cadence and to any Cadence Affiliate or Sublicensee; and

 (iii) agree not to assert the patent right embodying any Secondary Source Improvement disclosed pursuant to Sub-Clause 5.2(a)(i) against
Cadence, any Cadence Affiliate or Sublicensee in connection with the use, sale or resale of products produced according to the provisions of Sub-Clause 5.2(a)(ii). 
 (b) Cadence shall notify Solvay in the event that the sublicense agreement with the Secondary Source does not contain all of the provisions required under Sub-Clause 5.2(a), in which event Solvay shall be released
from its obligations under Sub-Clause 5.1. 
 (c) Cadence agrees that Solvay shall be released from its obligations under Sub-Clause 5.1 in
the event that, despite Cadence’s commercially reasonable efforts, the Secondary Source refuses, or materially breaches its obligations, to disclose any Secondary Source Improvement to Solvay, to grant Solvay the license to any Secondary Source
Improvement, and/or to make the non-assertion commitments with respect to the same, all as set forth under Sub-Clause 5.2; provided, however, that Solvay shall provide notice to Cadence and to the Secondary Source, specifying the nature of
the alleged breach by the Secondary Source, and that Cadence or the Secondary Source has not substantially remedied the alleged breach within sixty (60) days following the receipt of such notice. During such sixty (60) day period, Solvay
may temporarily suspend its disclosure obligations under Sub-clause 5.1. 
  

	 	5.3	Commencing twelve (12) months after the Secondary Source Effective Date and continuing on the anniversary of such date during the Improvement Period, Solvay and the
Secondary Source shall each provide Cadence with a statement certifying whether or not, during the immediately completed twelve (12) month period, there have been any Solvay Improvements, in the case of Solvay, or any Secondary Source
Improvements, in the case of the Secondary Source. Cadence shall notify 

  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	 
Solvay if it has knowledge that the Secondary Source refuses, or materially breaches its obligations to disclose any Secondary Source Improvement to Solvay
as required under Sub-clause 5.2(a)(i), and Cadence shall notify the Secondary Source if it has knowledge that Solvay refuses, or materially breaches its obligations to disclose any Solvay Improvements to the Secondary Source as required under
Sub-clause 5.1. 

  

	6.	CLAUSE 6 – CONSIDERATION AND PAYMENT CONDITIONS 

  

	 	6.1	Consideration 

 6.1.1 In consideration for the
rights to be granted to Cadence under Sub-Clauses 3.1 and 3.2, and upon the grant of such rights, the following amounts shall be payable by Cadence to Solvay following the Program Commencement Date, on the terms and conditions set forth in
Sub-Clause 6.3, below: 
 (a) a one-time license issue fee of ##### euros (##### €), and 
 (b) a royalty on Royalty Bulk Drug Substance (as such term is defined in Sub-Clause 6.2(b), below) purchased by Cadence, its Affiliates or Sublicensees
from the Secondary Source, which will be determined as follows: 
 (i) for #####, the applicable royalty rate shall be the lower of:
(A) #####, (B) #####, or (C) #####, or 
 (ii) for #####, the applicable royalty rate shall be the lower of: (A) #####,
(B) #####, or (C) #####. 
 6.1.2 In consideration for the transfer of Solvay Know-How to the Secondary Source under Sub-Clause 4.1,
and the provision of technical assistance services to the Secondary Source under Sub-Clause 4.2(a), Cadence shall pay to Solvay, on the payment terms and conditions set forth in Sub-Clause 6.3, below, a one-time know-how transfer fee of ##### Euros
(##### €). 
 6.1.3 For any further service requested pursuant to Sub-Clause
4.2(b), Cadence shall pay to Solvay a per-diem fee of ##### euros (##### €) for any engineer or PhD, and ##### euros (##### €) for any other specialist, providing such services in 2008, or traveling for such purpose. From the first
(1st) day of January 2009, this amount shall be annually increased or decreased according to the change in the Consumer Price Index (CPI) in
Belgium published by OCDE for the month of December of the preceding calendar year, as compared with the CPI of December 2007. 
 6.1.4
Cadence shall bear the reasonable traveling expenses, and the reasonable lodging and living expenses, of Solvay’s personnel providing technical assistance services hereunder, that are incurred by such personnel in connection with such services.

  

	 	6.2	Payment of royalties 

 (a) The royalty under
Sub-Clause 6.1.1(b) shall be paid on a yearly basis within sixty (60) days from the end of each calendar year, or portion thereof, for which they are due until the later of: 
 (i) #####, 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (ii) #####, or 
 (iii) #####. 
 Following such time, the rights granted under Sub-Clauses 3.1, 3.2 and 5.1(b) shall be fully
paid-up. 
 (b) Notwithstanding anything in this Agreement to the contrary, the royalty under Sub-Clause 6.1.1(b) shall only be due for any
Bulk Drug Substance purchased by Cadence, its Affiliates or Sublicensees, from the Secondary Source, the manufacture, use, supply or sale of which (i) would, but for the licenses conveyed herein, infringe a Valid Claim, or (ii) would
utilize any non-public Solvay Know-How or any non-public Solvay Improvement obtained from Solvay pursuant to this Agreement (the “Royalty Bulk Drug Substance”). 
 (c) Any payment of royalties according to Sub-Clause 6.2(a) shall be accompanied by a statement showing the total amount of Bulk Drug Substance purchased
from the Secondary Source by Cadence, its Affiliates and Sublicensees, and the total invoiced purchase price thereof, and supporting the calculation of the royalty due by Cadence to Solvay hereunder for the considered year, or portion thereof.
Cadence shall not be obligated to disclose in such report information that would disclose or permit the calculation of the purchase price paid to the Secondary Source if disclosure of such information would violate confidentiality obligations of
Cadence to the Secondary Source; provided, however, that in any event such information shall be made available for verification pursuant to audits under Sub-Clause 6.4. 
  

	 	6.3	Payment of fees 

 (a) The license issue fee due
under Sub-Clause 6.1.1(a) shall be paid according to the following schedule: ##### 
 (b) The Solvay Know-How transfer fee due under
Sub-Clause 6.1.2 shall be paid according to the following schedule: ##### 
 (c) Any amount due by Cadence pursuant to Sub-Clauses 6.1.3 and
6.1.4 shall be paid within thirty (30) days after receipt of Solvay’s corresponding invoices. 
  

	 	6.4	Records and Accounting 

 Cadence
shall keep true books of account containing complete and accurate records of all data necessary for computation of the royalties payable under this Agreement. Such books shall be retained for at least three (3) calendar years following the year
during which they are paid and shall be available during normal business hours and upon reasonable notice for inspection by an independent, certified public accountant selected by Solvay, and reasonably acceptable to Cadence, and acting on a
confidential basis, for the purpose of verifying statements and payments foreseen hereunder. 
 The cost of the audit is to be
paid by Solvay. However, if any report or payment furnished by Cadence is incorrect and results in an underpayment of more than ##### percent (#####%) of the amounts due to Solvay, Cadence shall reimburse Solvay for the cost of the audit within
thirty (30) days after receipt of Solvay’s invoice therefor. 
 The right under this Sub-Clause 6.4 may not be
exercised more than once in any calendar year. Once the books and records for a particular year, or portion thereof, have been audited pursuant to this Sub-Clause, they shall not be subject to subsequent re-audit. 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	6.5	Currency of Payments 

 (a) All payment by Cadence to
Solvay hereunder shall be made by wire transfer (or such other reasonable means as Solvay may direct) to the bank account of Solvay-CICC S.A., number. ##### with Fortis Bank, Brussels, or any other bank account expressly stipulated by Solvay.

 (b) Any payment of royalties hereunder shall be made in US dollars (USD). 
 For the payment of royalties due on sales invoiced by the Secondary Source to Cadence, its Affiliates or Sublicensees in currencies other than US dollars
(USD), the exchange rate applicable shall be the one published in the Wall Street Journal under the heading “Foreign Exchange” for the date three (3) working days prior to the date when the royalty payment falls due.

 (c) Any payment other than royalties hereunder shall be made in euros (EUR). 
  

	 	6.6	Tax Withholding 

 ##### The Parties
shall cooperate reasonably with each other to ensure that any amounts required to be withheld by either Party are reduced in an amount to the fullest extent permitted by applicable law. Any interest, penalties or other charges imposed by a
governmental authority as a result of a failure by the withholding Party to pay such taxes, levies or other duties shall be the responsibility of the withholding Party. No deduction shall be made, or a reduced amount shall be deducted, if the other
Party furnishes a document from the appropriate tax governmental authorities to the withholding Party certifying that the payments are exempt from such taxes, levies or other duties or subject to reduced tax rates, according to the applicable
convention for the avoidance of double taxation. ##### . 
  

	 	6.7	Overdue Payment 

 Payments provided for in this
Clause 6, when overdue, shall bear interest at a rate per annum equal to ##### percent (#####%) in excess of the one-year-EURIBOR (Euro Interbank Offered Rate) effective at the date such payment is due, and for the time period until such payment is
received by Solvay without prejudice of any other available remedies. 
 6.8 Notwithstanding anything in this Agreement or the Supply
Agreement to the contrary, in the event that this Agreement is terminated by either Party prior to the occurrence of the Program Commencement Date, none of the payments set forth in this Clause 6 shall be owed by Cadence to Solvay. 

 

	7.	CLAUSE 7 – CONFIDENTIALITY 

  

	 	7.1	Confidential Information 

 (a) In the course of the
performance of this Agreement, either Party may disclose to the other non-public information relating to the subject matter of this Agreement or the Supply Agreement which information shall be considered to be the disclosing Party’s
Confidential Information. Each Party agrees that it will take the same steps to protect the confidentiality of the other Party’s Confidential Information as it takes to protect its own proprietary and confidential information of a 

 
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
similar nature (but not less than with reasonable care). Each Party shall protect and keep confidential and shall not use, publish or otherwise disclose to
any third party, except as permitted by this Agreement, the Supply Agreement, or with the other Party’s written consent, the other Party’s Confidential Information. For clarity, (i) each Party may use the other Party’s
Confidential Information in the exercise of the rights and licenses conveyed herein, and (ii) this Sub-Clause 7.1 shall not be construed to prohibit the disclosure and use of Solvay’s Confidential Information by the Secondary Source
in connection with permitted manufacture and supply of Bulk Drug Substance under this Agreement. Each Party agrees to not use the other Party’s Confidential Information for any purpose other than as explicitly permitted under this Agreement.

 (b) Cadence shall be responsible for, and be guarantor of, the performance by the Secondary Source of its confidentiality obligations under
this Agreement, and shall cause the Secondary Source to comply with the same. Cadence shall require the Secondary Source to sign a reasonable and customary confidentiality agreement with Cadence containing obligations no less stringent than those
applying to the Parties hereunder. 
 (c) Solvay shall be responsible for, and be guarantor of, the performance by any subcontractors utilized
by Solvay or its Affiliates in connection with this Agreement or any Supply Agreement of the confidentiality obligations under this Agreement, and shall cause its subcontractors and equipment suppliers to comply with the same. Solvay shall require
its (and its Affiliates’) subcontractors to sign a reasonable and customary confidentiality agreement with Solvay. 
  

	 	7.2	Authorized Disclosures 

 (a) Each Party may disclose
Confidential Information of the other Party to the extent such disclosure is reasonably necessary for prosecuting or defending litigation, or complying with applicable law or governmental regulations. In particular, Cadence shall be entitled to
disclose that part of Solvay Confidential Information to governmental agencies such as the U.S. Food and Drug Agency and equivalent regulatory authorities in other jurisdictions, as required for Cadence, its Affiliates or Sublicensees, to obtain
appropriate regulatory approvals for the production and commercialization of drug products containing the Bulk Drug Substance. 
 In the event that either Party is obligated by law or regulation to make any such disclosure of the other Party’s Confidential Information, the Party so required to make such disclosure shall, except where impracticable (including with
respect to regulatory filings, patent filings or for necessary disclosures for example in the event of medical emergency), give reasonable advance notice of such disclosure requirement to the other Party and shall use its reasonable efforts to
secure confidential treatment of such Confidential Information required to be disclosed. 
 (b) Solvay shall be entitled to disclose to its
subcontractors and equipment suppliers that part of Cadence Confidential Information which is necessary for them to perform their activities, such as analyzing Bulk Drug Substance or any intermediate product produced through the Licensed Process, or
designing or constructing any equipment suitable for such analysis or such production. 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c) Cadence shall be entitled to disclose to the Secondary Source, that part of Solvay Confidential
Information which is necessary or useful for the Secondary Source to exploit the sublicense granted under Sub-Clause 3.1. 
  

	 	7.3	Exceptions 

 (a) The confidentiality obligations
under Sub-Clauses 7.1 and 7.2 shall not apply to that part of information which the receiving Party can demonstrate: 
 (i) was in the public
domain prior to its disclosure by the other Party, 
 (ii) has entered the public domain after its disclosure by the other Party through no
fault of the receiving Party, 
 (iii) was in possession of the receiving Party prior to direct, or indirect, disclosure by the other Party,

 (iv) has been received by the receiving Party from a third party giving reasonable evidence of its lawful possession and not imposing an
obligation of confidentiality, or 
 (v) was independently developed without use of or reference to the Confidential Information of the
disclosing Party. 
 (b) Information shall not be deemed to be within the above exceptions merely because such information is embraced by more
general information within any of such exceptions. Further, any combination of features shall not be deemed to be within such exceptions merely because individual features are within any of such exceptions, but only if the combination itself and its
principle of operation or utility are in like form within any such exception. 
  

	 	7.4	Duration 

 The obligations of
confidentiality, non disclosure and restricted use contemplated by this Clause 7 shall remain in force for the longer of: (a) the term of this Agreement; (b) the term of the Supply Agreement; or (c) ##### years after the expiration,
or termination for whatever cause, of this Agreement. 
  

	8.	CLAUSE 8 – REPRESENTATIONS AND WARRANTIES 

  

	 	8.1	Mutual Representations and Warranties 

 Each Party hereby represents and warrants to the other Party that, to the best of its knowledge, this Agreement is legal and valid obligation binding upon such Party and enforceable in accordance with its terms, and that the execution,
delivery and performance of this Agreement, by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a Party or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it. 
  

	 	8.2	Solvay Representation and Warranties 

 (a) Solvay
represents and warrants that it is entitled to grant the rights under Sub-Clauses 3.1 and 5.1(b), and that Solvay has not granted, and during the term of this Agreement will not grant, any right relating to Solvay Technology to any third party that
would conflict with the rights granted hereunder. Solvay represents that, to the best of its present knowledge, the Licensed Process and Solvay Know-How can be practiced by Solvay or the Secondary Source pursuant to the license hereunder without
infringing the rights of any third party. 
  
 ##### Certain information on this
page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) Solvay warrants that the documents provided under Sub-Clause 4.1 are correct and in sufficient
details to allow a Secondary Source having usual skills in fine organic chemistry to produce through the Licensed Process (as used by Solvay) Bulk Drug Substance meeting the Specifications. In the event of a duly established error or omission in
such documents, Solvay shall promptly make the appropriate modifications or corrections which shall be done at its expense, except to the extent that such error or omission is due to inaccurate information from Cadence or the Secondary Source.

 (c) Except as provided for in Sub-Clauses 8.1 and 8.2, Solvay makes no other representation or warranty with respect to the Bulk Drug
Substance produced by the Secondary Source, and shall not be held responsible nor liable for any costs, losses or damages, including consequential damages, with respect to any Bulk Drug Substance produced by the Secondary Source under the sublicense
granted hereunder. More particularly, except as provided for in Sub-Clauses 8.1 and 8.2, nothing in this Agreement shall be construed as: 
 (i) a warranty of Solvay for prosecuting, maintaining, keeping in force, or defending the validity of, any Solvay Patent, or any patent right claiming any Improvement of Solvay, 
 (ii) a warranty or representation of Solvay as to the validity or scope of Solvay Technology, or of any Improvement of Solvay, 
 (iii) a warranty or representation of Solvay that the practice of Solvay Technology, or of any Improvement of Solvay, is or will be free from
infringement of patent rights of third parties, 
 (iv) an obligation for Solvay to bring or prosecute actions or suits against third parties
for infringement of any Solvay Patent, or of any patent right claiming any Improvement of Solvay, or 
 (v) a warranty or guarantee of Solvay
as to the technical performance, the properties, the approvability by any appropriate governmental agency, the merchantability or the safety of use of any Bulk Drug Substance produced by the Secondary Source under the sublicense granted hereunder,
or of any drug product containing, or made using, such Bulk Drug Substance obtained from a Secondary Source. 
  

	 	8.3	Cadence Representations and Warranties 

 Cadence shall be responsible for, and be guarantor of, the performance by the Secondary Source of its obligations and undertakings under this Agreement. Cadence warrants that it shall cause any Secondary Source to sign an agreement
with Cadence to comply with the obligations pertinent to the Secondary Source contained in this Agreement, and shall provide to Solvay a redacted copy of such agreement. 
  

	 	8.4	Limitation of Liability 

 (a) Neither Party shall be
liable to the other for indirect incidental or consequential damages arising out of any of the terms or conditions of this Agreement or with respect to its performance. 
 (b) In any event, the total financial liability of Solvay under this Agreement, other than for fraudulent misrepresentation, death or injury caused by Solvay’s negligent or willful acts, but including the costs
of the modifications and corrections that Solvay might have to bear under Sub-Clause 8.2(b), shall not exceed U.S. ##### Dollars (US$#####). 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	9.	CLAUSE 9 – TERM AND TERMINATION 

  

	 	9.1	Term 

 This Agreement shall become effective on the
Date of this Agreement, and unless earlier terminated as provided under Sub-Clause 9.2, or pursuant to Article 10.6 of the Supply Agreement, shall thereafter remain in effect, until the later of: 
 (a) the twelfth (12th) anniversary of the First Supply Date, 
 (b) the
twelfth (12th) anniversary of the end of the Improvement Period, or 
 (c) the date of expiration of the last to expire of any Valid Claim of any Solvay Patent that would be infringed by the manufacture and supply of the Bulk
Drug Substance made by the Secondary Source . 
  

	 	9.2	Early Termination 

 This Agreement
may be terminated: 
 (a) upon mutual written agreement between the Parties; 
 (b) by either Party as a result of a material breach or default in the performance of any obligation, condition or covenant of this Agreement by the other
Party if such default or non compliance shall not have been remedied within ninety (90) days after receipt by the defaulting Party of a notice thereof from the terminating Party, unless the defaulting Party is in the process of attempting in
good faith to remedy such default, in which case the ninety (90) day cure shall be extended by an additional sixty (60) days. For the sake of clarity, (i) the non satisfaction by Cadence of its purchase commitment to Solvay as set
forth under Sub-Clause 2.1(b) shall be considered as a material breach or default hereunder, except if Cadence is expressly released from such commitment and, (ii) any failure by a Secondary Source to comply with its obligations under
Sub-Clause 5.2 or 5.3 of this Agreement shall not be considered a material breach or default hereunder by Cadence; 
 (c) by either
Party upon ten (10) days written notice to the other Party if the other Party ceases to do business (other than in connection with a merger or sale of assets or other transaction in connection with which this Agreement is assigned pursuant to
Clause 10.3 to an entity that does not cease to do business), or makes any assignment of substantially all of its assets for the benefit of creditors, or places substantially all of its assets in the hands of a receiver or judicial manager,
goes into liquidation, or is dissolved, wound up, confiscated, sequestered or in any other way transferred into state ownership; 
 (d) by
either Party in case the Supply Agreement is terminated pursuant to Article 10.2(e) thereof; 
 (e) by Solvay in the event Cadence, any
Cadence Affiliate, any Sublicensee, the Secondary Source or any entity or person which controls, is controlled by or is under common control with the Secondary Source, disputes the validity of Solvay Technology, or of any Improvement of Solvay;
provided, however, such dispute shall not have been remedied within 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
ninety (90) days after receipt by Cadence of a notice thereof from Solvay, unless Cadence is in the process of attempting in good faith to remedy such
default, in which case the ninety (90) day cure shall be extended by an additional sixty (60) days. For the sake of clarity, “dispute” under this Sub-Clause means oppose any Solvay Patent, or any patent right embodying any
Solvay Improvement, before any Patent Office, or national court; or 
 (f) by Cadence at any time and for any reason upon sixty (60) days
prior written notice to Solvay. 
  

	 	9.3	Effects of Expiration or Termination 

 (a) Any early
termination of this Agreement by either Party pursuant to the provisions of Sub-Clause 9.2 shall be without prejudice to the right of such Party to recover any amount of money due to it under this Agreement, and to the rights or remedies of such
Party in respect of any antecedent breach of this Agreement by the other Party if any. 
 (b) In the event of termination of this Agreement
for whatever cause, in addition to the other obligations of the Parties hereunder, each Party shall, within thirty (30) days after the receipt of a timely request from the other Party, destroy or return to the other Party or to the other
Party’s designee all of such other Party’s property, including all Confidential Information, in its possession and as far as Cadence is concerned, all Solvay Confidential Information in the possession of the Secondary Source, except to the
extent required to be retained by Applicable Law or to comply with such Party’s continuing obligations hereunder or under the License Agreement. 
 (c) After the expiration, or early termination, of this Agreement: 
 (i) the confidentiality, non disclosure
and restricted use obligations set forth hereunder shall continue thereafter in accordance with Sub-Clause 7.4; and 
 (ii) the rights
granted to Cadence under Sub-Clauses 3.1, 3.2 and 5.1(b) shall continue thereafter, except that such rights shall cease immediately upon termination by Solvay pursuant to Sub-Clauses 9.2(b), 9.2(c) or 9.2(e), by Cadence pursuant to Sub-Clause
9.2(f), by either party pursuant to Sub-Clause 9.2(d) of this Agreement or Sub-Clause 10.6 of the Supply Agreement, or by mutual agreement pursuant to Sub-Clause 9.2(a). 
 (d) In the event of termination of this Agreement by Cadence pursuant to Sub-Clause 9.2(b) or 9.2(c): 
 (i)
the rights granted to Cadence under Sub-Clauses 3.1, 3.2 and 5.1(b) shall continue, 
 (ii) Cadence shall be released from its obligation to
pay royalties in consideration for such continuing rights, and 
 (iii) concerning Cadence’s obligation to purchase a minimum of #####
percent (#####%) of the aggregate annual requirements of Cadence, Cadence’s Affiliates and Sublicensees, for Bulk Drug Substance from Solvay, 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 (1) such obligation shall remain applicable in case of termination pursuant to Sub-Clause 9.2(b) after
the Secondary Source Effective Date, and 
 (2) Cadence shall be released from such obligation in case of termination pursuant to Sub-Clause
9.2(c). 
 (e) Except as otherwise expressly provided hereunder or under the Supply Agreement, the termination of this Agreement shall not
affect the Supply Agreement. 
  

	10.	CLAUSE 10 – MISCELLANEOUS 

  

	 	10.1	Applicable Law 

 This Agreement
shall be governed by and construed in accordance with the laws of England and Wales, except that no conflict of laws provision shall be applied to make the laws of any other jurisdiction applicable to this Agreement. 
  

	 	10.2	Arbitration 

 The Parties shall
attempt in good faith to resolve amicably all disputes resulting from, concerning the validity of, or arising in connection with, this Agreement prior to initiating arbitration proceedings. Any such dispute which is not settled amicably by the
Parties through such good faith attempts shall be finally settled under the rules of arbitration of the International Chamber of Commerce by three (3) arbitrators appointed in accordance with such rules. The arbitration shall be held in London,
England. The proceedings and award shall be in the English language, and all documentary evidence not in English shall be submitted with an English translation. The decision and/or award rendered by the arbitrators shall be written (specifically
stating the arbitrators’ findings of facts as well as the reasons upon which the arbitrators’ decision is based). The Parties agree that the decision of the arbitrators shall be the sole, exclusive and binding remedy between them regarding
any and all disputes, controversies, claims and counterclaims presented to the arbitrator(s). Any decision of the arbitrators may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement.
Pending the establishment of the arbitral tribunal or pending the arbitral tribunal’s determination of the merits of the controversy, either Party may seek from a court of competent jurisdiction any interim or provisional relief that may be
necessary to protect the rights or property of that Party. 
  

	 	10.3	Assignment 

 Neither Party hereto
shall, without prior written consent of the other Party, assign this Agreement and the rights and obligations hereunder, in whole or in part, except that, upon thirty (30) days prior written notification, 
 (a) Solvay may assign its rights and obligations under this Agreement in whole or in part, without the prior written consent of Cadence, (i) to any
Affiliate of Solvay, or (ii) in connection with the sale, merger or transfer of substantially all of the stock or assets of SOLVAY SA or the sale, merger or transfer of substantially all of the interests in or the assets of Peptisyntha S.A., to
any party who meets financial and ethical standards generally acceptable within the pharmaceutical industry, provided such Affiliate or assignee, as the case may be, agrees to be bound by the terms of this Agreement; and 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) Cadence may assign its rights and obligations under this Agreement in whole or in part, in connection
with the sale, merger or transfer of all or substantially all of the assets of Cadence relating to Bulk Drug Substance, to any party who meets financial and ethical standards generally acceptable within the pharmaceutical industry, provided such
assignee, as the case may be, agrees to be bound by the terms of this Agreement. 
  

	 	10.4	Binding Effect 

 This Agreement
shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns. 
  

	 	10.5	Entire Agreement 

 This Agreement,
together with the Supply Agreement, is the entire agreement between the Parties, and shall terminate and supersede any prior written or oral promises or representations between the Parties not incorporated herein, including the Confidentiality
Agreement and the Letter of Intent. In the event any discrepancy exists between any provision of this Agreement, and any provision of the Supply Agreement, this Agreement shall prevail, except that the Supply Agreement shall prevail in case the
discrepancy relates to the supply of Bulk Drug Substance by Solvay. No amendment or modification of the terms of this Agreement shall be binding on either Party unless reduced to writing and signed by the respective authorized officers of the
Parties. 
  

	 	10.6	Force Majeure 

 Neither Party shall
be liable to the other for loss or damage, or, except as provided herein, have any right to terminate this Agreement by virtue of an occurrence which prevents, delays or interferes with the performance by a Party of any of its obligations hereunder,
if such occurs by reason of any Act of God, flood, fire, explosion, casualty or accident, or war, revolution, civil commotion, acts of public enemies, blockage or embargo, or any law, order of proclamation of any government, strike or other labor
trouble, failure of suppliers to deliver materials, equipment or machinery, interruption of or delay in transportation, or any other cause whatsoever, whether similar or dissimilar to those above enumerated, beyond the reasonable control of such
Party, if and only if, the Party affected shall have used its best efforts to avoid such occurrence. In such an event, the Party affected shall notify the other and shall use its best efforts to perform its obligations as soon as possible.

  

	 	10.7	Headings 

 All headings, titles and
captions in this Agreement are for convenience only and shall not be of any force or substance 
  

	 	10.8	Independent contractors – Relation of the Parties 

 Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. 
 All activities by the Parties hereunder shall be performed by them as independent contractors. Neither Party shall incur any debts or make
any commitments for the other Party, except to extent, if at all, specifically provided herein. 
 No right, express or
implied, is granted by this Agreement to either Party to use in any manner the name of the other or any other trade name or trade mark of the other in connection with the performance of this Agreement. 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 No term of this Agreement shall be enforceable under the Contracts (Rights of Third
Parties) Act 1999 by a person who is not a party to this Agreement, but this shall not affect any right or remedy of any third party which exists or is available other than under that Act. 
  

	 	10.9	Notices 

 All notices and demands
required or permitted to be given or made pursuant to this Agreement shall be in writing and shall be deemed given if delivered personally or by given by facsimile transmission (return receipt requested), postage prepaid, or sent by express courier
service, properly addressed to the address of the Party to be notified as shown below: 
 If to Solvay: 
 SOLVAY SA 
 Attention to: General Manager
Solvay Peptides, 
 Rue de Ransbeek 310, 
 B-1120 Brussels, Belgium 
 Facsimile : 32-2-264.34.70 
 With a copy to: 
 SOLVAY SA 
 Attention to: Head of IP Agreements Department 
 Rue de Ransbeek 310, 
 B-1120 Brussels, Belgium 
 If to Cadence: 
 CADENCE PHARMACEUTICALS, INC., 
 Attention to : Legal Department 
 12481
High Bluff Drive, Suite 200, 
 San Diego, California, 92130, USA 
 Facsimile : (858) 436-8510 
 or to such
other address as to which either Party may notify the other. Any notice sent by facsimile transmission or telex shall be followed within twenty-four (24) hours by a signed notice sent by first class mail, postage prepaid. 
  

	 	10.10	Performance by Affiliates 

 Cadence
recognizes that Solvay may perform some or all of its obligations under this Agreement through its Affiliates as specified in this Agreement, provided however, that Solvay shall remain responsible and be guarantor of the performance by its
Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Solvay recognizes that Cadence may perform some or all of its obligations under this Agreement through its Affiliates as
specified in this Agreement, provided however, that Cadence shall remain responsible for and be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such
performance. 
  

	 	10.11	Publicity 

 The Parties agree that
any public announcement of the execution of this Agreement shall only be by one or more press releases mutually agreed to by the Parties. The failure of a Party to return a draft press release with its proposed amendments or modifications to such
press release to the other Party within five (5) business days of such Party’s receipt of such press release shall be deemed as such Party’s approval of such press release as received by such Party. 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Solvay and Cadence agree that, except as may otherwise be required by applicable laws,
regulations, rules (including applicable rules of any public stock exchange), or orders, the terms and conditions of this Agreement and the transactions contemplated herein shall be confidential and shall not be made public by either Party without
the prior written consent of the other. Notwithstanding the foregoing, either Party may disclose the terms and conditions of this Agreement and the transactions contemplated herein, under reasonable and customary obligations of confidentiality, to
actual and potential investors, acquirers, licensees and others on a need to know basis. 
 This Sub-Clause 10.11 shall
not be construed to limit or prohibit either Party from making any disclosure required by applicable laws, regulations, rules (including applicable rules of any public stock exchange) or orders, and either Party may disclose information regarding
this Agreement and the transactions contemplated herein that have previously been publicly disclosed. 
  

	 	10.12	 Severability 

 If any
provision of this Agreement is determined to be illegal or unenforceable by any Court of law or any competent governmental or other authority, the remaining provisions shall be severable and enforceable in accordance with their terms so long as this
Agreement without such terms or provisions does not fail of its essential purpose. The Parties shall negotiate in good faith to replace any such illegal or unenforceable provisions with suitable substitute provisions which will maintain as far as
possible the purposes and the effect of this Agreement. 
  

	 	10.13	 Waiver 

 Failure of either
Party to insist upon strict observance of, or compliance with any of, the terms of this Agreement in one or more instances shall not be deemed to be a waiver of its rights to insist upon such observance or compliance with the other terms hereof, at
that point in time or in the future. 
 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in two
original copies by their respective duly authorized representatives as of the date first hereabove written. 
  

									
	SOLVAY SA	 		 	CADENCE PHARMACEUTICALS, INC.
			
	/s/ Vincent De Cuyper	 		 	/s/ Theodore R. Schroeder
	Name:	 	Vincent De Cuyper	 		 	Name:	 	Theodore R. Schroeder
	Title:	 	 Member of the Executive Committee Solvay SA
 General
Manager of the Chemicals Sector
	 		 	Title:	 	President and CEO

  
 ##### Certain information on this
page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

									
				
	/s/ Jean-Michel Mesland	 		 		 	
	Name:	 	Jean-Michel Mesland	 		 		 	
	Title:	 	 Member of the Executive Committee Solvay SA
 General
Manager for Research and Technologies
	 		 		 	

 Exhibits: 
 Exhibit A: Possible secondary sources 
 Exhibit B: Documents for the transfer of Solvay Know-How 
  
 ##### Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A – POSSIBLE SECONDARY SOURCES 
 ##### 
  
 ##### Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B – DOCUMENTS FOR TRANSFER OF SOLVAY KNOW-HOW 
 Listing of documents which constitute the initial technology transfer package 
 ##### 
  
 #####
Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.Form of Senior Indenture

 FORM OF SENIOR INDENTURE 
 EXHIBIT 4.06 
  
  
 LABORATORY CORPORATION OF AMERICA HOLDINGS 
 ISSUER 
 AND 
 THE BANK OF NEW YORK MELLON
TRUST COMPANY, N.A. 
 TRUSTEE 
 INDENTURE 
 DATED AS OF
[                    ], [                    ]

 SENIOR DEBT SECURITIES 

 CROSS-REFERENCE TABLE1 
  

			
	 Section of Trust Indenture Act of 1939, as Amended
	  	Indenture
	 310(a)
	  	7.10
	 310(b)
	  	7.08; 7.10
	 310(c)
	  	Inapplicable
	 311(a)
	  	7.11
	 311(b)
	  	7.11
	 311(c)
	  	Inapplicable
	 312(a)
	  	2.12; 2.13(a)
	 312(b)
	  	2.13(c)
	 312(c)
	  	Inapplicable
	 313(a)
	  	7.06
	 313(b)
	  	7.06
	 313(c)
	  	7.06
	 313(d)
	  	7.06
	 314(a)
	  	4.09; 4.11
	 314(b)
	  	Inapplicable
	 314(c)
	  	12.07
	 314(d)
	  	Inapplicable
	 314(e)
	  	12.07
	 314(f)
	  	Inapplicable
	 315(a)
	  	7.01
	 315(b)
	  	7.05
	 315(c)
	  	7.01
	 315(d)
	  	7.01
	 315(e)
	  	6.11; 7.07
	 316(a)
	  	6.04
	 316(b)
	  	6.07
	 316(c)
	  	8.01
	 317(a)
	  	6.08
	 317(b)
	  	4.04
	 318(a)
	  	12.09

  
  

	 1
	 This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the
interpretation of any of its terms or provisions. 

  

 i 

 TABLE OF CONTENTS2 
  

					
	 	  	 	  	Page
	 ARTICLE I DEFINITIONS
	  	1
	 SECTION 1.01
	  	 DEFINITIONS OF TERMS.
	  	1
	 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES
	  	8
	 SECTION 2.01
	  	 DESIGNATION AND TERMS OF SECURITIES.
	  	8
	 SECTION 2.02
	  	 FORM OF SECURITIES AND TRUSTEE’S CERTIFICATE.
	  	10
	 SECTION 2.03
	  	 DENOMINATIONS: PROVISIONS FOR PAYMENT.
	  	10
	 SECTION 2.04
	  	 EXECUTION AND AUTHENTICATION.
	  	12
	 SECTION 2.05
	  	 REGISTRATION OF TRANSFER AND EXCHANGE.
	  	12
	 SECTION 2.06
	  	 TEMPORARY SECURITIES.
	  	13
	 SECTION 2.07
	  	 MUTILATED, DESTROYED, LOST OR STOLEN SECURITIES.
	  	14
	 SECTION 2.08
	  	 CANCELLATION.
	  	15
	 SECTION 2.09
	  	 BENEFITS OF INDENTURE.
	  	15
	 SECTION 2.10
	  	 AUTHENTICATING AGENT.
	  	15
	 SECTION 2.11
	  	 GLOBAL SECURITIES.
	  	16
	 SECTION 2.12
	  	 COMPANY TO FURNISH TRUSTEE NAMES AND ADDRESSES OF SECURITYHOLDERS.
	  	17
	 SECTION 2.13
	  	 PRESERVATION OF INFORMATION; COMMUNICATIONS WITH SECURITYHOLDERS.
	  	17
	 SECTION 2.14
	  	 CUSIP NUMBERS.
	  	18
	 SECTION 2.15
	  	 OUTSTANDING SECURITIES.
	  	18
	 ARTICLE III REDEMPTION OF SECURITIES
	  	18
	 SECTION 3.01
	  	 REDEMPTION.
	  	18
	 SECTION 3.02
	  	 NOTICES TO TRUSTEE.
	  	18
	 SECTION 3.03
	  	 SELECTION OF SECURITIES TO BE REDEEMED.
	  	19
	 SECTION 3.04
	  	 NOTICE OF REDEMPTION.
	  	19
	 SECTION 3.05
	  	 EFFECT OF NOTICE OF REDEMPTION.
	  	20
	 SECTION 3.06
	  	 DEPOSIT OF REDEMPTION PRICE.
	  	20
	 SECTION 3.07
	  	 SECURITIES REDEEMED IN PART.
	  	20
	 ARTICLE IV COVENANTS
	  	20
	 SECTION 4.01
	  	 PAYMENT OF SECURITIES.
	  	20
	 SECTION 4.02
	  	MAINTENANCE OF OFFICE OR AGENCY FOR REGISTRATION OF TRANSFER, EXCHANGE AND PAYMENT OF SECURITIES.	  	21
	 SECTION 4.03
	  	 APPOINTMENT TO FILL A VACANCY IN THE OFFICE OF TRUSTEE.
	  	21

  
  

	 2
	 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of
any of its terms or provisions. 

  

 ii 

					
	 SECTION 4.04
	  	 PROVISION AS TO PAYING AGENT.
	  	21
	 SECTION 4.05
	  	 MAINTENANCE OF CORPORATE EXISTENCE.
	  	22
	 SECTION 4.06
	  	 COMPLIANCE CERTIFICATE.
	  	22
	 SECTION 4.07
	  	 FURTHER INSTRUMENTS AND ACTS.
	  	23
	 SECTION 4.08
	  	 COMMISSION REPORTS.
	  	23
	 ARTICLE V SUCCESSOR COMPANY
	  	23
	 SECTION 5.01
	  	 WHEN COMPANY MAY MERGE OR TRANSFER ASSETS.
	  	23
	 ARTICLE VI DEFAULTS AND REMEDIES
	  	24
	 SECTION 6.01
	  	 EVENTS OF DEFAULT.
	  	24
	 SECTION 6.02
	  	 ACCELERATION.
	  	25
	 SECTION 6.03
	  	 OTHER REMEDIES.
	  	26
	 SECTION 6.04
	  	 WAIVER OF PAST DEFAULTS.
	  	26
	 SECTION 6.05
	  	 CONTROL BY MAJORITY.
	  	26
	 SECTION 6.06
	  	 LIMITATION ON SUITS.
	  	27
	 SECTION 6.07
	  	 RIGHTS OF HOLDERS TO RECEIVE PAYMENT.
	  	27
	 SECTION 6.08
	  	 COLLECTION SUIT BY TRUSTEE.
	  	27
	 SECTION 6.09
	  	 TRUSTEE MAY FILE PROOFS OF CLAIM.
	  	27
	 SECTION 6.10
	  	 PRIORITIES.
	  	28
	 SECTION 6.11
	  	 UNDERTAKING FOR COSTS.
	  	28
	 SECTION 6.12
	  	 WAIVER OF STAY OR EXTENSION LAWS.
	  	28
	 ARTICLE VII CONCERNING THE TRUSTEE
	  	29
	 SECTION 7.01
	  	 DUTIES OF TRUSTEE.
	  	29
	 SECTION 7.02
	  	 RIGHTS OF TRUSTEE.
	  	30
	 SECTION 7.03
	  	 INDIVIDUAL RIGHTS OF TRUSTEE.
	  	31
	 SECTION 7.04
	  	 TRUSTEE’S DISCLAIMER.
	  	31
	 SECTION 7.05
	  	 NOTICE OF DEFAULTS.
	  	31
	 SECTION 7.06
	  	 REPORTS BY TRUSTEE TO HOLDERS.
	  	31
	 SECTION 7.07
	  	 COMPENSATION AND INDEMNITY.
	  	32
	 SECTION 7.08
	  	 REPLACEMENT OF TRUSTEE.
	  	32
	 SECTION 7.09
	  	 SUCCESSOR TRUSTEE BY MERGER.
	  	33
	 SECTION 7.10
	  	 ELIGIBILITY; DISQUALIFICATION.
	  	34
	 SECTION 7.11
	  	 PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY.
	  	34
	 ARTICLE VIII CONCERNING THE SECURITYHOLDERS
	  	34
	 SECTION 8.01
	  	 EVIDENCE OF ACTION BY SECURITYHOLDERS.
	  	34
	 SECTION 8.02
	  	 PROOF OF EXECUTION BY SECURITYHOLDERS.
	  	35
	 SECTION 8.03
	  	 WHO MAY BE DEEMED OWNERS.
	  	35
	 SECTION 8.04
	  	 CERTAIN SECURITIES OWNED BY COMPANY DISREGARDED.
	  	35
	 SECTION 8.05
	  	 ACTIONS BINDING ON FUTURE SECURITYHOLDERS.
	  	36
	 ARTICLE IX SUPPLEMENTAL INDENTURES
	  	36
	 SECTION 9.01
	  	 SUPPLEMENTAL INDENTURES WITHOUT THE CONSENT OF SECURITYHOLDERS.
	  	36

  

 iii 

					
	 SECTION 9.02 
	  	 SUPPLEMENTAL INDENTURES WITH CONSENT OF SECURITYHOLDERS.
	  	37
	 SECTION 9.03 
	  	 EFFECT OF SUPPLEMENTAL INDENTURES.
	  	38
	 SECTION 9.04 
	  	 SECURITIES AFFECTED BY SUPPLEMENTAL INDENTURES.
	  	38
	 SECTION 9.05 
	  	 EXECUTION OF SUPPLEMENTAL INDENTURES.
	  	39
	 SECTION 9.06 
	  	 PAYMENT FOR CONSENT
	  	39
	ARTICLE X SATISFACTION AND DISCHARGE; DEFEASANCE	  	40
	 SECTION 10.01 
	  	 SATISFACTION AND DISCHARGE.
	  	40
	 SECTION 10.02 
	  	 DEFEASANCE.
	  	41
	 SECTION 10.03 
	  	 CONDITIONS TO DEFEASANCE.
	  	41
	 SECTION 10.04 
	  	 APPLICATION OF TRUST MONEY.
	  	42
	 SECTION 10.05 
	  	 REPAYMENT TO COMPANY.
	  	43
	 SECTION 10.06 
	  	 INDEMNITY FOR GOVERNMENTAL OBLIGATIONS.
	  	43
	 SECTION 10.07 
	  	 REINSTATEMENT.
	  	43
	ARTICLE XI IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS	  	43
	 SECTION 11.01 
	  	 NO RECOURSE.
	  	43
	ARTICLE XII MISCELLANEOUS PROVISIONS	  	44
	 SECTION 12.01 
	  	 EFFECT ON SUCCESSORS AND ASSIGNS.
	  	44
	 SECTION 12.02 
	  	 ACTIONS BY SUCCESSOR.
	  	44
	 SECTION 12.03 
	  	 SURRENDER OF COMPANY POWERS.
	  	44
	 SECTION 12.04 
	  	 NOTICES.
	  	44
	 SECTION 12.05 
	  	 GOVERNING LAW.
	  	44
	 SECTION 12.06 
	  	 TREATMENT OF SECURITIES AS DEBT.
	  	45
	 SECTION 12.07 
	  	 COMPLIANCE CERTIFICATES AND OPINIONS.
	  	45
	 SECTION 12.08 
	  	 PAYMENTS ON BUSINESS DAYS.
	  	45
	 SECTION 12.09 
	  	 CONFLICT WITH TRUST INDENTURE ACT.
	  	46
	 SECTION 12.10 
	  	 COUNTERPARTS.
	  	46
	 SECTION 12.11 
	  	 SEPARABILITY.
	  	46
	 SECTION 12.12 
	  	 ASSIGNMENT.
	  	46
	 SECTION 12.13 
	  	 WAIVER OF JURY TRIAL.
	  	46
	 SECTION 12.14 
	  	 FORCE MAJEURE.
	  	46

  

 iv 

 INDENTURE 
 INDENTURE, dated as of [                    ],
[            ], between LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking
association, as trustee (the “Trustee”): 
 WHEREAS, for its lawful corporate purposes, the Company has duly authorized the
execution and delivery of this Indenture to provide for the issuance of unsecured senior debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or
more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee; 
 WHEREAS, to provide the terms and conditions upon which the Securities are to be authenticated, issued and delivered, the Company has duly authorized the execution of this Indenture; and 
 WHEREAS, all things necessary to make this Indenture a valid and legally binding agreement of the Company, in accordance with its terms, have been done.

 NOW, THEREFORE, in consideration of the premises and the purchase of the Securities by the holders thereof, it is mutually covenanted and
agreed as follows for the equal and ratable benefit of the holders of Securities or of series thereof. 
 ARTICLE I 
 DEFINITIONS 
 SECTION
1.01        DEFINITIONS OF TERMS. 
 The terms defined in this Section (except as in this
Indenture otherwise expressly provided or unless the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as
well as the singular. All other terms used in this Indenture that are defined in the Trust Indenture Act, or that are by reference in said Trust Indenture Act defined in the Securities Act (except as herein otherwise expressly provided or unless the
context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument. 
 “ACQUIRED INDEBTEDNESS” means Indebtedness of a Person (i) existing at the time such Person becomes a Subsidiary or (ii) assumed in
connection with the acquisition of assets by such Person, in each case, other than Indebtedness incurred in connection with, or in contemplation of, such Person becoming a Subsidiary or such acquisition, as the case may be. For purposes of
Section 4.08, any Acquired Indebtedness shall not be deemed to have been incurred until 270 days from the date (A) the Person obligated on such Acquired Indebtedness 

 
becomes a Subsidiary of the Company or (B) the acquisition of assets, in connection with which such Acquired Indebtedness was assumed, is consummated.

 “ADJUSTED TREASURY RATE” means, with respect to any redemption date, (i) the yield, under the heading which represents the
average for the immediately preceding week, appearing in the most recently published statistical release designated “H.15(519)” or any successor publication which is published weekly by the Board of Governors of the Federal Reserve System
and which establishes yields on actively traded United States Treasury securities adjusted to constant maturity under the caption “Treasury Constant Maturities,” for the maturity corresponding to the Comparable Treasury Issue (if no
maturity is within three months before or after the remaining term of the Securities of the series being redeemed, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue shall be determined and the
Adjusted Treasury Rate shall be interpolated or extrapolated from such yields on a straight line basis, rounding to the nearest month) or (ii) if such release (or any successor release) is not published during the week preceding the calculation
date or does not contain such yields, the rate per year equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue (expressed as a percentage of its principal amount) assuming a price for the Comparable Treasury Issue
equal to the Comparable Treasury Price for such redemption date, in each case calculated on the third Business Day preceding the redemption date, plus the make-whole spread specified in the Board Resolution, Officers’ Certificate or
supplemental indenture establishing the terms of the series of Securities being redeemed in accordance with Section 2.01. 
 “AFFILIATE” means, as applied to any Person, (i) any other Person, directly or indirectly, Controlling or Controlled by or under direct or indirect common Control with such specified Person or (ii) any Person who is a
director or officer (A) of such Person, (B) of any Subsidiary of such Person or (C) of any Person described in clause (i) above. 
 “AUTHENTICATING AGENT” means an authenticating agent with respect to all or any of the series of Securities appointed with respect to all or any series of the Securities by the Trustee pursuant to
Section 2.10. 
 “BANKRUPTCY LAW” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.

 “BOARD OF DIRECTORS” means the Board of Directors of the Company or any duly authorized committee of such Board. 
 “BOARD RESOLUTION” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been duly adopted
by the Board of Directors and to be in full force and effect on the date of such certification. 
 “BUSINESS DAY” means a day other
than a Legal Holiday. 
 “CAPITALIZED LEASE” means any obligation of a Person to pay rent or other amounts incurred with respect to
real property or equipment acquired or leased by such Person and used in its business that is required to be recorded as a capital lease in accordance with GAAP. 
  

 2 

 “CAPITAL STOCK” means any and all shares, interests, participations or other equivalents
(however designated) of capital stock of a corporation, any and all equivalent ownership interests in a Person (other than a corporation) and any and all warrants or options to purchase any of the foregoing. 
 “CERTIFICATE” means a certificate signed by the principal executive officer, the principal financial officer or the principal accounting
officer of the Company. The Certificate need not comply with the provisions of Section 12.07. 
 “COMMISSION” means the
Securities and Exchange Commission. 
 “COMPANY” means Laboratory Corporation of America Holdings, a corporation duly organized and
existing under the laws of the State of Delaware until a successor replaces it in accordance with Article V and thereafter means the successor and, for purposes of any provision contained herein and required by the TIA, each other obligor on the
Securities. 
 “COMPARABLE TREASURY ISSUE” means the United States Treasury security selected by the Quotation Agent as having a
maturity comparable to the remaining term from the redemption date to the maturity date of the Securities being redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of
corporate debt securities of comparable maturity to the remaining term of the Securities. 
 “COMPARABLE TREASURY PRICE” means,
with respect to any redemption date, if clause (ii) of the Adjusted Treasury Rate is applicable, the average of three, or such lesser number as is obtained by the Trustee, Reference Treasury Dealer Quotations for such redemption date.

 “CONTROL” shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or
policies of a person, whether through the ownership of voting securities, by contract or otherwise, and the terms “Controlled” and “Controlling” shall have meanings correlative thereto. 
 “CORPORATE TRUST OFFICE” means the principal office of the Trustee at which, at any particular time, this corporate trust account shall be
principally administered, which office at the date hereof is located at 10161 Centurion Parkway, Jacksonville, FL 32256. 
 “COVENANT
DEFEASANCE OPTION” has the meaning given in Section 10.02. 
 “CUSTODIAN” means any receiver, trustee, assignee,
liquidator or similar official under any Bankruptcy Law. 
 “DEFAULT” means any event, act or condition which is, or that with
notice or lapse of time, or both, would constitute an Event of Default. 
 “DEFAULTED INTEREST” has the meaning given in
Section 2.03. 
 “DEPOSITARY” means, with respect to Securities of any series, for which the Company shall determine that such
Securities will be issued as a Global Security, The Depository Trust 

  

 3 

 
Company, New York, New York, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, or other applicable statute or
regulation, which, in each case, shall be designated by the Company pursuant to either Section 2.01 or 2.11. 
 “EVENT OF
DEFAULT” means, with respect to Securities of a particular series any event specified in Section 6.01, continued for the period of time, if any, therein designated. 
 “EXCHANGE ACT” means the Securities Exchange Act of 1934, as amended, or any successor statute or statutes thereto. 
 “GAAP” means generally accepted accounting principles in the United States of America in effect from time to time, including those set forth in
the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements of pronouncements of the Financial Accounting Standards Board or such other entity as are approved by a
significant segment of the accounting profession. 
 “GLOBAL SECURITY” means, with respect to any series of Securities, a Security
executed by the Company and delivered by the Trustee to the Depositary or pursuant to the Depositary’s instruction, all in accordance with the Indenture, which shall be registered in the name of the Depositary or its nominee. 
 “GOVERNMENTAL OBLIGATIONS” means securities that are (i) direct obligations of the United States of America for the payment of which its
full faith and credit is pledged or (ii) obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the payment of which is unconditionally guaranteed as a full faith and
credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary receipt issued by a bank (as defined in Section 3(a)(2) of the
Securities Act) as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by such custodian for the account of the holder of such depositary receipt;
provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the Governmental
Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt. 
 “HEREIN”, “HEREOF” and “HEREUNDER”, and other words of similar import, refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. 
 “INDEBTEDNESS” of any Person means, without duplication (i) any obligation of such Person for money borrowed, (ii) any obligation of
such Person evidenced by bonds, debentures, notes or other similar instruments, (iii) any reimbursement obligation of such Person in respect of letters of credit or other similar instruments which support financial obligations which would
otherwise become Indebtedness, and (iv) any obligation of such Person under Capitalized Leases; provided, however, that “Indebtedness” of such Person shall not include any obligation of such Person to any Subsidiary of such Person or
to any Person with respect to which such Person is a Subsidiary. 
  

 4 

 “INDENTURE” means this instrument as originally executed or as it may from time to time be
supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof, including, for all purposes of this instrument and any such supplemental indenture, the provisions of the Trust Indenture Act
that are deemed to be a part of and govern this instrument and any such supplemental indenture, respectively. The term “Indenture” shall also include the terms of particular series of Securities established as contemplated by
Section 2.01. 
 “INTEREST PAYMENT DATE”, when used with respect to any installment of interest on a Security of a particular
series, means the date specified in such Security or in or pursuant to a Board Resolution, in an Officers’ Certificate or in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of interest with
respect to Securities of that series is due and payable. 
 “LEGAL DEFEASANCE OPTION” has the meaning given in Section 10.02.

 “LEGAL HOLIDAY” means a Saturday, a Sunday or a day on which commercial banking institutions are not required to be open in the
State of New York. 
 “LIEN” means any mortgage, pledge, hypothecation, encumbrance, lien or other security interest. 

“MAKE-WHOLE AMOUNT” means the sum, as determined by a Quotation Agent, of the present values of the scheduled payments of principal and
interest (exclusive of interest to the redemption date) from the redemption date to the maturity date of the Securities being redeemed, in each case discounted to the redemption date on a semi-annual basis, assuming a 360-day year consisting of
twelve 30-day months, at the Adjusted Treasury Rate, plus accrued and unpaid interest on the principal amount of the Securities being redeemed to the redemption date. 
 “OFFICERS’ CERTIFICATE” means a certificate signed by the President or a Vice President and by the Treasurer or an Assistant Treasurer or the Controller or an Assistant Controller or the Secretary or an
Assistant Secretary of the Company that is delivered to the Trustee in accordance with the terms hereof. Each such certificate shall include the statements provided for in Section 12.07, if and to the extent required by the provisions thereof.

 “OPINION OF COUNSEL” means an opinion in writing of legal counsel, who may be an employee of or counsel for the Company that is
delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section 12.07, if and to the extent required by the provisions thereof. 
 “ORIGINAL ISSUE DISCOUNT SECURITY” means any Security which provides for an amount less than the principal amount thereof to be due and payable
upon a declaration of acceleration of the Stated Maturity thereof. 
 “PAYING AGENT” has the meaning given in Section 4.04.

 “PERMITTED INDEBTEDNESS” as to a series of Securities means (i) Indebtedness outstanding on the date of the issuance of
Securities of such series; (ii) intercompany 

  

 5 

 
Indebtedness or Preferred Stock to the extent owing to or held by the Company or another Subsidiary; (iii) any Permitted Acquired Indebtedness;
(iv) Indebtedness under performance bonds or with respect to workers’ compensation claims, in each case incurred in the ordinary course of business; and (v) Indebtedness of any Subsidiary Guarantor; provided that if such Subsidiary
shall cease to be a Subsidiary Guarantor, such Indebtedness will be treated as incurred at that time and will no longer constitute Permitted Indebtedness pursuant to this clause (v). 
 “PERSON” means any individual, corporation, limited liability company, partnership, joint-venture, joint-stock company, unincorporated
organization or government or any agency or political subdivision thereof. 
 “PREDECESSOR SECURITY” of any particular Security
means every previous Security evidencing all or a portion of the same debt as that evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section 2.07 in lieu of a lost,
destroyed or stolen Security shall be deemed to evidence the same debt as the lost, destroyed or stolen Security. 
 “PREFERRED
STOCK” means, with respect to any Person, any and all shares of preferred stock (however designated) issued by such Person, that is entitled to preference or priority over one or more series or classes of Capital Stock issued by such Person
upon any distribution of such Person’s property and assets, whether by dividend or on liquidation, whether now outstanding, or issued after the date hereof. 
 “PRINCIPAL OF” a Security means the principal of the Security plus the premium, if any, payable on the Security which is due or overdue or is to become due at the relevant time. 
 “QUOTATION AGENT” means the Reference Treasury Dealer selected by the Company. 
 “REFERENCE TREASURY DEALER” means Banc of America Securities LLC and its successors and assigns, and two other nationally recognized investment
banking firms selected by the Company that are primary U.S. government securities dealers. 
 “REFERENCE TREASURY DEALER
QUOTATIONS” means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Trustee, of the bid and asked prices for the Comparable Treasury Issue, expressed in each case as a percentage of its
principal amount, quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m., New York City time, on the third Business Day preceding such redemption date. 
 “RESPONSIBLE OFFICER” when used with respect to the Trustee means any officer within the corporate trust department of the Trustee, including
any vice president, assistant treasurer, any trust officer or any other officer or assistant officer of the Trustee customarily performing functions similar to those performed by the Persons who at the time shall be such officers, respectively, or
to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with the particular subject and who shall have direct responsibility for the administration of this Indenture. 
  

 6 

 “SECURITIES” means the debt Securities authenticated and delivered under this Indenture.

 “SECURITIES ACT” means the Securities Act of 1933, as amended, or any successor statute or statutes thereto. 
 “SECURITYHOLDER”, “HOLDER of SECURITIES”, “REGISTERED HOLDER”, “HOLDER” or other similar term, means the Person
or Persons in whose name or names a particular Security shall be registered on the books of the Company kept for that purpose in accordance with the terms of this Indenture. 
 “SECURITY REGISTER” has the meaning given in Section 2.05. 
 “SECURITY REGISTRAR” has the meaning given in Section 2.05. 
 “STATED MATURITY”
means, with respect to any Security of a series, the date specified in such Security as the fixed date on which the final payment of principal of such Security is due and payable. 
 “SUBSIDIARY” means, with respect to any Person, (i) any corporation at least a majority of whose outstanding Voting Stock shall at the
time be owned, directly or indirectly, by such Person or by one or more of its Subsidiaries or by such Person and one or more of its Subsidiaries, (ii) any general partnership, limited liability company, joint venture or similar entity, at
least a majority of whose outstanding partnership or similar interests shall at the time be owned by such Person, or by one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries and (iii) any limited partnership of
which such Person or any of its Subsidiaries is a general partner. 
 “SUBSIDIARY GUARANTOR” means any Subsidiary of the Company if
and so long as such Subsidiary provides a guarantee of the Securities substantially in the form of Annex A of this Indenture. 
 “TRUSTEE” means The Bank of New York Mellon Trust Company, N.A. and, subject to the provisions of Article VII, shall also include its successors and assigns, and, if at any time there is more than one Person acting in such
capacity hereunder, “Trustee” shall mean each such Person. The term “Trustee” as used with respect to a particular series of the Securities shall mean the trustee with respect to that series. 
 “TRUST INDENTURE ACT” and “TIA” means the Trust Indenture Act of 1939, as amended, subject to the provisions of Sections 9.01, 9.02,
and 12.09, as in effect at the date of execution of this instrument. 
 “UNIFORM COMMERCIAL CODE” means the New York Uniform
Commercial Code as in effect from time to time. 
 “VOTING STOCK”, as applied to stock of any Person, means shares, interests,
participations or other equivalents in the equity interest (however designated) in such Person having ordinary voting power for the election of a majority of the directors (or the equivalent) of 

  

 7 

 
such Person, other than shares, interests, participations or other equivalents having such power only by reason of the occurrence of a contingency.

 ARTICLE II 
 ISSUE,
DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 
 SECTION 2.01
        DESIGNATION AND TERMS OF SECURITIES. 
 The aggregate principal amount of Securities that
may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to a Board
Resolution, pursuant to an Officers’ Certificate or pursuant to one or more indentures supplemental hereto. Prior to the initial issuance of Securities of any series, there shall be established in or pursuant to a Board Resolution, and set
forth in an Officers’ Certificate, or established in an Officers’ Certificate or established in one or more indentures supplemental hereto: 
 (1)         the title of the Security of the series including CUSIP numbers (which shall distinguish the Securities of the series from all other Securities); 
 (2)         any limit upon the aggregate principal amount of the Securities of that series that may be
authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of, transfer of, or in exchange for, or in lieu of, other Securities of that series); 
 (3)         the date or dates on which the principal of the Securities of the series is payable and the place(s)
of payment; 
 (4)         the rate or rates at which the Securities of the series shall bear
interest or the manner of calculation of such rate or rates, if any; 
 (5)         the date or dates
from which such interest shall accrue, the Interest Payment Dates on which such interest will be payable or the manner of determination of such Interest Payment Dates, the place(s) of payment, and the record date or other method for the
determination of holders to whom interest is payable on any such Interest Payment Dates; 
 (6)
        the right, if any, to extend the interest payment periods and the duration of such extension; 
 (7)         the period or periods within which, the price or prices at which and the terms and conditions upon which, Securities of the series may be redeemed, in whole or in part, at the option of
the Company; 
 (8)         the obligation, if any, of the Company to redeem or purchase Securities
of the series or at the option of a holder thereof and the period or periods within which, the price or 

  

 8 

 
prices at which, and the terms and conditions upon which, Securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such
obligation; 
 (9)         the form of the Securities of the series including the form of the
Trustee’s certificate of authentication for such series; 
 (10)       if other than denominations of one
thousand U.S. dollars ($1,000) or any integral multiple thereof, the denominations in which the Securities of the series shall be issuable; 
 (11)       any and all other terms with respect to such series (which terms shall not be inconsistent with the terms of this Indenture, as amended by any supplemental indenture) including any terms which may be
required by or advisable under U.S. laws or regulations or advisable in connection with the marketing of Securities of that series; 
 (12)
      whether the Securities of the series are issuable as a Global Security and, in such case, the identity of the Depositary for such series; 
 (13)       whether the Securities of the series will be convertible into shares of common stock or other securities of the
Company and, if so, the terms and conditions upon which such Securities will be so convertible, including the conversion price and the conversion period; 
 (14)       if other than the principal amount thereof, the portion of the principal amount of Securities of the series which shall be payable upon declaration of acceleration of the
maturity thereof pursuant to Section 6.01 and the amount that will be deemed to be the principal amount of the Securities for any other purpose; 
 (15)       any additional or different Events of Default or restrictive covenants provided for with respect to the Securities of the series and any change in the right of the Trustee or
the Holders to declare the principal amount of the Securities of a series due and payable; 
 (16)
      whether the Securities of the series shall not be defeasible pursuant to Section 10.02 and, if other than by a Board Resolution, the manner in which any election by the Company to defease such Securities
shall be evidenced; and 
 (17)       if other than the currency of the United States of America, the currency,
currencies or currency units in which the principal of or any premium or interest on any Securities of the series shall be payable and the manner of determining the equivalent thereof in the currency of the United States of America for any purpose.

 All Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided in or
pursuant to any such Board Resolution, Officers’ Certificate or in any indentures supplemental hereto. If any of the terms of the series are established by action taken pursuant to a Board Resolution, a copy of an appropriate record of such
action shall be certified by the Secretary or an Assistant Secretary of the Company and delivered to the Trustee at or prior to the delivery of the Officers’ Certificate setting forth the terms of the series. Securities of any particular series
may be issued at various times, with 

  

 9 

 
different dates on which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which
rates of interest may be determined, with different dates on which such interest may be payable and with different redemption dates. Notwithstanding Section 2.01(2) and unless otherwise expressly provided with respect to a series of Securities,
the aggregate principal amount of a series of Securities may be increased and additional Securities of such series may be issued up to the maximum aggregate principal amount authorized with respect to such series as increased. 
 SECTION 2.02         FORM OF SECURITIES AND TRUSTEE’S CERTIFICATE. 
 The Securities of any series and the Trustee’s certificate of authentication to be borne by such Securities shall be substantially of the tenor and
purport as set forth in one or more indentures supplemental hereto or as provided in or pursuant to a Board Resolution or in an Officers’ Certificate. The Securities may have such letters, numbers or other marks of identification or designation
and such legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any rule or
regulation made pursuant thereto or with any rule or regulation of any stock exchange on which Securities of that series may be listed, or to conform to usage. 
 SECTION 2.03         DENOMINATIONS: PROVISIONS FOR PAYMENT. 
 The Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral multiple thereof, subject to Section 2.01(10). The Securities of a particular series shall bear
interest payable on the dates and at the rates specified or provided for with respect to that series. Except as contemplated by Section 2.01(17), the principal of and the interest on the Securities of any series, as well as any premium thereon
in case of redemption thereof prior to maturity, shall be payable in the coin or currency of the United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that
purpose in the Borough of Manhattan, the City and State of New York; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in
the Security Register. Each Security shall be dated the date of its authentication by the Trustee. Except as contemplated by Section 2.01(4), interest on the Securities shall be computed on the basis of a 360-day year composed of twelve 30-day
months. Except as contemplated by Section 2.01(5), the interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for Securities of that series shall be paid to the Person in
whose name said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such interest installment. In the event that any Security of a particular series or portion thereof is called for
redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Security will be paid upon presentation and surrender of such Security as
provided in Section 3.03. Any interest on any Security that is payable, but is not punctually paid or duly provided for, on any Interest Payment Date for Securities of the same series (herein called “Defaulted Interest”) shall
forthwith cease to be payable to the registered holder on the relevant regular record date by 

  

 10 

 
virtue of having been such holder; and such Defaulted Interest shall be paid by the Company, at its election, as provided in clause (1) or clause
(2) below: 
 (1)         The Company may make payment of any Defaulted Interest on Securities
to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following manner: the
Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal
to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust for
the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10 days prior
to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the expense of
the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be mailed, first class postage prepaid, to each Securityholder at his or her address as it appears in the Security Register
(as hereinafter defined), not less than 10 days prior to such special record date. Notice of the proposed payment of such Defaulted Interest and the special record date therefor having been mailed as aforesaid, such Defaulted Interest shall be paid
to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered on such special record date. 
 (2)
        The Company may make payment of any Defaulted Interest on any Securities in any other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities may be
listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. 
 Unless otherwise set forth in or pursuant to a Board Resolution, in an Officers’ Certificate or one or more indentures supplemental hereto
establishing the terms of any series of Securities pursuant to Section 2.01 hereof, the term “regular record date” as used in this Section with respect to a series of Securities with respect to any Interest Payment Date for such
series shall mean either the fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the first day of
a month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section 2.01 hereof shall occur, if such Interest Payment Date is the fifteenth day of a month, whether or not such date is a
Business Day. Subject to the foregoing provisions of this Section, each Security of a series delivered under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest
accrued and unpaid, and to accrue, that were carried by such other Security. 
  

 11 

 SECTION 2.04         EXECUTION AND AUTHENTICATION.

 The Securities shall be signed on behalf of the Company by any of two of its President, any Vice President, its Treasurer, any
Assistant Treasurer, its Secretary or any Assistant Secretary. Signatures may be in the form of a manual or facsimile signature. The Company may use the facsimile signature of any Person who shall have been a President or Vice President thereof, or
of any Person who shall have been the Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary thereof, notwithstanding the fact that at the time the Securities shall be authenticated and delivered or disposed of such Person shall
have ceased to be the President or a Vice President, or the Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary, of the Company. The Securities may contain such notations, legends or endorsements required by law, stock
exchange rule or usage. A Security shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. The Securities shall be dated the date of their authentication. Such signature shall be
conclusive evidence that the Security so authenticated has been duly authenticated and delivered hereunder and that the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this
Indenture, the Company may deliver Securities of any series executed by the Company to the Trustee for authentication, together with a written order of the Company for the authentication and delivery of such Securities, signed by its President or
any Vice President and its Secretary or any Assistant Secretary, and the Trustee in accordance with such written order shall authenticate and deliver such Securities. In authenticating such Securities and accepting the additional responsibilities
under this Indenture in relation to such Securities, the Trustee shall be provided with, and (subject to Section 7.01) shall be fully protected in relying upon, an Opinion of Counsel stating that the form and terms thereof have been established
in conformity with the provisions of this Indenture and that such Securities, when authenticated and delivered by the Trustee and issued by the Company in the manner and subject to any conditions specified in such Opinion of Counsel, will constitute
valid and legally binding obligations of the Company enforceable in accordance with their terms, subject to any Bankruptcy Law or other insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to
or affecting creditors’ rights and to general equity principles and that applicable laws and legal requirements (with reasonable and customary exceptions and qualification for such an Opinion of Counsel) in respect to the execution and delivery
by the Company of such Securities have been complied with. The Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect the Trustee’s own rights, duties or immunities
under the Securities and this Indenture or otherwise in a manner that is not reasonably acceptable to the Trustee. 
 SECTION 2.05
        REGISTRATION OF TRANSFER AND EXCHANGE. 
 (a)
        Securities of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose in the Borough of Manhattan, the City and State of New York, for
other Securities of such series of authorized denominations, with the same terms, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, all as provided in this
Section. In respect of any Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or 

  

 12 

 
Securities of the same series that the Securityholder making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding.

 (b)         The Company shall keep, or cause to be kept, at its office or agency designated for
such purpose in the Borough of Manhattan, the City and State of New York, or such other location designated by the Company a register or registers (herein referred to as the “Security Register”) in which, subject to such reasonable
regulations as it may prescribe, the Company shall register the Securities and the transfers of Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of
registering Securities and transfer of Securities as herein provided shall be appointed as authorized by or pursuant to a Board Resolution or an Officers’ Certificate (the “Security Registrar”). Upon surrender for transfer of any
Security at the office or agency of the Company designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities
of the same series as the Security presented for a like aggregate principal amount. All Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if so required by the Company or
the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar, duly executed by the registered holder or by such holder’s duly authorized attorney in writing.

 (c)         No service charge shall be made for any exchange or registration of transfer of
Securities, or issue of new Securities in case of partial redemption of any series, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge in relation thereto (including the fees and expenses of the
Trustee), other than exchanges pursuant to Section 2.06, Section 3.07 and Section 9.04 not involving any transfer. 
 The
Company shall not be required (i) to issue, exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the mailing of a notice of redemption of less than all the
outstanding Securities of the same series and ending at the close of business on the day of such mailing, nor (ii) to register the transfer of or exchange any Securities of any series or portions thereof called for redemption. The provisions of
this Section 2.05 are, with respect to any Global Security, subject to Section 2.11 hereof. 
 SECTION 2.06
        TEMPORARY SECURITIES. 
 Pending the preparation of definitive Securities of any series,
the Company may execute, and the Trustee shall authenticate and deliver, temporary Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive
Securities in lieu of which they are issued, but with such omissions, insertions and variations as may be appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed by the
Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish
definitive Securities of such series and thereupon any or all temporary Securities of such series may be surrendered in exchange 

  

 13 

 
therefor (without charge to the holders), at the office or agency of the Company designated for the purpose in the Borough of Manhattan, the City and State
of New York, and the Trustee shall authenticate and such office or agency shall deliver in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to
the effect that definitive Securities need not be executed and furnished until further notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive
Securities of such series authenticated and delivered hereunder. 
 SECTION 2.07
        MUTILATED, DESTROYED, LOST OR STOLEN SECURITIES. 
 In case any temporary or definitive
Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next succeeding sentence) shall execute, and upon the Company’s request the Trustee (subject as aforesaid) shall authenticate and deliver, a new
Security of the same series, bearing a number not contemporaneously outstanding, in exchange and substitution for the mutilated Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant
for a substituted Security shall furnish to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the
Company and the Trustee evidence to their satisfaction of the destruction, loss or theft of the applicant’s Security and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the same upon the written
request or authorization of any officer of the Company. Upon the issuance of any substituted Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and
any other expenses (including the fees and expenses of the Trustee) connected therewith. In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a
substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or indemnity as they
may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such Security and of the ownership thereof. Every replacement Security
issued pursuant to the provisions of this Section shall constitute an additional contractual obligation of the Company whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and
shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing
provisions are exclusive with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or
hereafter enacted to the contrary with respect to the replacement or payment of negotiable instruments or other securities without their surrender. 
  

 14 

 SECTION 2.08         CANCELLATION. 
 All Securities surrendered for the purpose of payment, redemption, exchange or registration of transfer shall, if surrendered to the Company or any
paying agent, be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as expressly required or permitted by any of the provisions of this
Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the Trustee may dispose of canceled Securities in accordance with
its standard procedures and deliver a certificate of disposition to the Company upon its request therefor. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate as a redemption or satisfaction of
the indebtedness represented by such Securities unless and until the same are delivered to the Trustee for cancellation. 
 SECTION 2.09
        BENEFITS OF INDENTURE. 
 Nothing in this Indenture or in the Securities, express or
implied, shall give or be construed to give to any Person, other than the parties hereto and the holders of the Securities any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or
provision herein contained; all such covenants, conditions and provisions being for the sole benefit of the parties hereto and of the holders of the Securities. 
 SECTION 2.10         AUTHENTICATING AGENT. 
 So long as any
of the Securities of any series remain outstanding there may be an Authenticating Agent for any or all such series of Securities which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the
Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption thereof, and Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as
if authenticated by the Trustee hereunder. All references in this Indenture to the authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each Authenticating Agent shall be
acceptable to the Company and shall be a corporation that has a combined capital and surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it is doing business
to conduct a trust business, and that is otherwise authorized under such laws to conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be eligible
in accordance with these provisions, it shall resign immediately. Any Authenticating Agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time (and upon request by the Company
shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent and to the Company. Upon resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may
appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder
as if originally named as an Authenticating Agent pursuant hereto. Any corporation into which an Authenticating Agent may 

  

 15 

 
be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which such
Authenticating Agent shall be a party, or any corporation succeeding to all or substantially all the corporate agency or corporate trust business of an Authenticating Agent, shall continue to be an Authenticating Agent, provided that such
corporation shall be otherwise eligible under this Section, without the execution or filing of any paper or any further act on the part of the Trustee or the Authenticating Agent. 
 SECTION 2.11         GLOBAL SECURITIES. 
 (a)         If the Company shall establish pursuant to Section 2.01 that the Securities of a particular
series are to be issued as a Global Security, then the Company shall execute and the Trustee shall, in accordance with Section 2.04, authenticate and deliver, a Global Security that 
 (1)         shall represent, and shall be denominated in an amount equal to the aggregate
principal amount of, all or a portion of the outstanding Securities of such series, 
 (2)
        shall be registered in the name of the Depositary or its nominee, 
 (3)
        shall be delivered by the Trustee to the Depositary or pursuant to the Depositary’s instruction, and 
 (4)         shall bear a legend substantially to the following effect: “Except as otherwise provided in Section 2.11 of the Indenture, this Security may be
transferred, in whole but not in part, only to the Depositary, another nominee of the Depositary or to a successor Depositary or to a nominee of such successor Depositary.” 
 (b)         Notwithstanding the provisions of Section 2.05, the Global Security of a series may be
transferred, in whole but not in part and in the manner provided in Section 2.05, only to the Depositary for such series, another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by
the Company or to a nominee of such successor Depositary. 
 (c)         If at any time the
Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary for such series or if at any time the Depositary for such series shall no longer be registered or in good standing under the
Exchange Act, or other applicable statute or regulation, and a successor Depositary for such series is not appointed by the Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, this
Section 2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section 2.05, the Trustee will authenticate and deliver the Securities of such series in definitive registered form without
coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In addition, the Company may at any time determine that the
Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section 2.11 shall no longer apply to the Securities of such series. In such event the Company will execute and subject to Section 2.05, the
Trustee, upon receipt of an Officers’ Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized denominations, and in an
aggregate principal 

  

 16 

 
amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange of the Global Security for
such Securities in definitive registered form without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to
this Section 2.11(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver
such Securities to the Depositary for delivery to the Persons in whose names such Securities are so registered. 
 SECTION 2.12
        COMPANY TO FURNISH TRUSTEE NAMES AND ADDRESSES OF SECURITYHOLDERS. 
 The Company will
furnish or cause to be furnished to the Trustee 
 (1)         not more than 15 days
after each regular record date (as defined in Section 2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the
Company shall not be obligated to furnish or cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company, and 
 (2)         at such other times as the Trustee may request in writing within 30 days after the
receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished; 
 provided, however, that, in either case, no such list need be furnished for any series for which the Trustee shall be the Security Registrar. 
 SECTION 2.13         PRESERVATION OF INFORMATION; COMMUNICATIONS WITH SECURITYHOLDERS. 
 (a)         The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the holders of Securities contained
in the most recent list furnished to it as provided in Section 2.12 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if acting in such capacity). 
 (b)         The Trustee may destroy any list furnished to it as provided in Section 2.12 upon receipt of a
new list so furnished. 
 (c)         Securityholders may communicate as provided in
Section 312(b) of the Trust Indenture Act with other Securityholders with respect to their rights under this Indenture or under the Securities. 
  

 17 

 SECTION 2.14         CUSIP NUMBERS. 
 The Company in issuing the Securities may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP”
numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any notice of a
redemption and that reliance may be placed only on the other identification numbers printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers. The Company will promptly notify the Trustee
in writing of any change in the “CUSIP” numbers. 
 SECTION 2.15         OUTSTANDING
SECURITIES. 
 Securities of a series outstanding at any time are all Securities of such series authenticated by the Trustee except for
those canceled by it, those delivered to it for cancellation and those described in this Section 2.15 as not outstanding. Subject to the provisions of Section 8.04, a Security of a series does not cease to be outstanding because the
Company or an Affiliate of the Company holds the Security. 
 If a Security is replaced pursuant to Section 2.07, it ceases to be
outstanding unless the Trustee and the Company receive proof satisfactory to them that the replaced Security is held by a protected person (as such term is defined in Section 8-303 of the Uniform Commercial Code). 
 If the Paying Agent segregates and holds in trust, in accordance with this Indenture, on a redemption date or at Stated Maturity money sufficient to pay
all principal and interest payable on that date with respect to the Securities of a series (or a portion thereof) to be redeemed or maturing, as the case may be, then on and after that date such Securities (or portions thereof) cease to be
outstanding and interest on them ceases to accrue. 
 ARTICLE III 
 REDEMPTION OF SECURITIES 
 SECTION 3.01
        REDEMPTION. 
 (a)         The Company may redeem
the Securities of any series issued hereunder on and after the dates and as set forth herein and in accordance with the terms established for such series pursuant to Section 2.01 hereof. 
 (b)         Unless otherwise provided for in Section 2.01 hereof, the Company may redeem the Securities of
any series at any time at a redemption price equal to the greater of (1) 100% of the principal amount of the Securities being redeemed plus accrued and unpaid interest to the redemption date or (2) the Make-Whole Amount for the Securities
of the series being redeemed. 
 SECTION 3.02         NOTICES TO TRUSTEE. 
 If the Company elects to redeem Securities of any series issued hereunder pursuant to Section 3.01, it shall notify the Trustee in writing of the
redemption date and the principal 

  

 18 

 
amount of Securities to be redeemed. The Company shall give each notice to the Trustee provided for in this Section at least 45 days before the redemption
date unless the Trustee consents to a shorter period. Such notice shall be accompanied by an Officers’ Certificate and an Opinion of Counsel to the effect that such redemption will comply with the conditions herein. 
 SECTION 3.03         SELECTION OF SECURITIES TO BE REDEEMED. 
 If fewer than all the Securities of any series are to be redeemed, the Trustee shall select the Securities to be redeemed pro rata or by lot or by a
method that complies with applicable legal and securities exchange requirements, if any, and that the Trustee in its sole discretion shall deem to be fair and appropriate and in accordance with methods generally used at the time of selection by
fiduciaries in similar circumstances. The Trustee shall make the selection from outstanding Securities of a series not previously called for redemption. The Trustee may select for redemption portions of the principal of Securities that have
denominations larger than $1,000. Securities and portions of them the Trustee selects to be redeemed shall be in principal amounts of $1,000 or a whole multiple of $1,000. Provisions of this Indenture that apply to Securities called for redemption
also apply to portions of Securities called for redemption. The Trustee shall notify the Company promptly of the Securities or portions of Securities to be redeemed. 
 SECTION 3.04         NOTICE OF REDEMPTION. 
 At least 30 days
but not more than 60 days before a date for redemption of Securities of any series, the Company shall mail a notice of redemption by first-class mail to each Holder of Securities to be redeemed at such Holder’s registered address. 

The notice shall identify the Securities to be redeemed (including CUSIP numbers) and shall state: 
 1.         the redemption date; 
 2.         a description of how the redemption price will be calculated; 
 3.         the name and address of the Paying Agent; 
 4.         that Securities called for redemption must be surrendered to the Paying Agent to
collect the redemption price; 
 5.         if fewer than all the outstanding
Securities of any series are to be redeemed, the identification and principal amounts of the particular Securities to be redeemed; 
 6.         that, unless the Company defaults in making such redemption payment, interest on Securities (or portion thereof) called for redemption ceases to accrue on and after the redemption date; and

 7.         that no representation is made as to the correctness or accuracy of the
CUSIP number, if any, listed in such notice or printed on the Securities. 
  

 19 

 The Trustee shall give the notice of redemption in the Company’s name and at the Company’s
expense. The Company shall provide the Trustee with the information required by this Section. In such event the Company shall give the Trustee 10 days (or such shorter notice as shall be agreed to by the Trustee) prior notice prior to the delivery
of the notice. 
 SECTION 3.05         EFFECT OF NOTICE OF REDEMPTION. 
 Once notice of redemption is mailed, Securities called for redemption become due and payable on the redemption date and at the redemption price stated in
the notice. Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price stated in the notice, which shall include accrued interest to the redemption date (subject to the right of Holders of record on the relevant record
date to receive interest due on the related interest payment date). Failure to give notice or any defect in the notice to any Holder shall not affect the validity of the notice to any other Holder. 
 SECTION 3.06         DEPOSIT OF REDEMPTION PRICE. 
 On the Business Day next preceding a redemption date, the Company shall deposit with the Paying Agent (or, if the Company or a Subsidiary is the Paying
Agent, shall segregate and hold in trust) money sufficient to pay the redemption price of all Securities to be redeemed on such date other than Securities or portions of Securities called for redemption which have been delivered by the Company to
the Trustee for cancellation. On or after the redemption date, interest shall cease to accrue on such Securities or portions thereof called for redemption so long as the Company has deposited with the Paying Agent funds sufficient to pay the
principal of, plus accrued but unpaid interest, if any, on the Securities to be redeemed. 
 SECTION 3.07
        SECURITIES REDEEMED IN PART. 
 Upon surrender of a Security that is redeemed in part,
the Company shall execute and the Trustee shall authenticate for the Holder (at the Company’s expense) a new Security equal in principal amount to the unredeemed portion of the Security surrendered. 
 ARTICLE IV 
 COVENANTS

 SECTION 4.01         PAYMENT OF SECURITIES. 
 The Company shall promptly pay the principal of and interest on the Securities on the dates and in the manner provided herein and established with
respect to such Securities and in this Indenture. Principal and interest shall be considered paid on the date due if on such date the Trustee or the Paying Agent holds in accordance with this Indenture money sufficient to pay all principal and
interest then due. 
 Notwithstanding anything to the contrary contained in this Indenture, the Company may, to the extent it is required to
do so by law, deduct or withhold income or other similar taxes imposed by applicable law from principal or interest payments hereunder. 
  

 20 

 The Company shall pay interest on overdue principal at the rate specified therefor in the Securities, and
subject to Section 2.11, it shall pay interest on overdue installments of interest at the same rate to the extent lawful. 
 SECTION
4.02         MAINTENANCE OF OFFICE OR AGENCY FOR REGISTRATION OF TRANSFER, EXCHANGE AND PAYMENT OF SECURITIES. 
 So long as any of the Securities shall remain outstanding, the Company shall maintain an office or agency in the Borough of Manhattan, The City of New York, State of New York, where the Securities of a series may be
surrendered for exchange or registration of transfer as in this Indenture provided, and where notices and demands to or upon the Company in respect to such Securities may be served, and where such Securities may be presented or surrendered for
payment. The Company may also from time to time designate one or more other offices or agencies where Securities of a series may be presented or surrendered for any and all such purposes and may from time to time rescind such designations; provided,
however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the Borough of Manhattan, The City of New York, State of New York for such purposes. The Company shall give
to the Trustee prompt written notice of the location of any such office or agency and of any change of location thereof. The Company initially appoints the Trustee, The Bank of New York Mellon Trust Company, N.A., 10161 Centurion Parkway,
Jacksonville, FL 32256, for each of said purposes. In case the Company shall fail to maintain any such office or agency or shall fail to give such notice of the location or of any change in the location thereof, such surrenders, presentations and
demands may be made and notices may be served at the principal office of the Trustee, and the Company hereby appoints the Trustee its agent to receive at the aforesaid office all such surrenders, presentations, notices and demands. The Trustee shall
give the Company prompt notice of any change in location of the Trustee’s principal office. 
 SECTION 4.03
        APPOINTMENT TO FILL A VACANCY IN THE OFFICE OF TRUSTEE. 
 The Company, whenever
necessary to avoid or fill a vacancy in the office of Trustee, shall appoint, in the manner provided in Section 7.08, a Trustee, so that there shall at all times be a Trustee hereunder. 
 SECTION 4.04         PROVISION AS TO PAYING AGENT. 
 (a)         If the Company shall appoint one or more paying agents for all or any series of the Securities (each
a “Paying Agent” and collectively, the “Paying Agents”) other than the Trustee, it shall cause such Paying Agent to execute and deliver to the Trustee an instrument in which such agent shall undertake, subject to the provisions
of this Section 4.04, 
 (1)         that it shall hold all sums held by it as
such agent for the payment of the principal of or interest on the Securities of any series such sums which have been paid to it by the Company (or by any other obligor on the Securities) in trust for the benefit of the Holders of the Securities of
such series and shall notify the Trustee of the receipt of sums to be so held, 
  

 21 

 (2)         that it shall give the Trustee notice
of any failure by the Company (or by any other obligor on the Securities) to make any payment of the principal of or interest on the Securities of any series when the same shall be due and payable, 
 (3)         that it shall at any time during the continuance of any Event of Default specified in
Section 6.01(1) or 6.01(2), upon the written request of the Trustee, deliver to the Trustee all sums so held in trust by it, and 
 (4)         acknowledge, accept and agree to comply in all aspects with the provisions of this Indenture relating to the duties, rights and liabilities of such Paying Agent.

 (b)         If the Company shall not act as its own Paying Agent, it shall, by the opening of
business (New York City time) on each due date of the principal and interest on any Security, deposit with such Paying Agent a sum in same day funds sufficient to pay the principal of or interest so becoming due, such sum to be held in trust for the
benefit of the Holders of Securities of a series entitled to such principal of or interest, and (unless such Paying Agent is the Trustee) the Company shall promptly notify the Trustee of its failure so to act. 
 (c)         If the Company shall act as its own Paying Agent, it shall, by the opening of business (New York City
time) on each due date of the principal and interest on any Security, set aside, segregate and hold in trust for the benefit of the persons entitled thereto, a sum sufficient to pay such principal or interest so becoming due and shall notify the
Trustee of any failure to take such action. 
 (d)         Anything in this Section 4.04 to the
contrary notwithstanding, the Company may, at any time, for the purpose of obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay or cause to be paid to the Trustee all sums held in trust by it, or any Paying Agent
hereunder, as required by this Section 4.03, such sums to be held by the Trustee upon the trusts herein contained. 
 (e)
        Anything in this Section 4.04 to the contrary notwithstanding, the agreement to hold sums in trust as provided in this Section 4.04 is subject to the provisions of Sections 10.05 and 10.07.

 SECTION 4.05         MAINTENANCE OF CORPORATE EXISTENCE. 
 So long as any of the Securities shall remain outstanding, the Company shall at all times (except as otherwise provided or permitted elsewhere in this
Indenture) do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence and franchises. 
 SECTION 4.06         COMPLIANCE CERTIFICATE. 
 The Company shall deliver to the
Trustee within 120 days after the end of each fiscal year of the Company an Officers’ Certificate stating that in the course of the performance by the signers of their duties as Responsible Officers of the Company they would normally have
knowledge of any Default and whether or not the signers know of any Default or Event of 

  

 22 

 
Default that occurred during such period. If they do, the certificate shall describe the Default or Event of Default, its status and what action the Company
is taking or proposes to take with respect thereto. The Company also shall comply with TIA Section 314(a)(4). Delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee’s receipt
of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which the Trustee is
entitled to rely exclusively on Officers’ Certificates). 
 SECTION 4.07         FURTHER
INSTRUMENTS AND ACTS. 
 Upon request of the Trustee or as necessary, the Company shall execute and deliver such further instruments and
do such further acts as may be reasonably necessary or proper to carry out more effectively the purpose of this Indenture. 
 SECTION 4.08
        COMMISSION REPORTS. 
 Without regard to whether the Company is subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act, the Company shall file with the Commission (so long as permitted by the Commission) and provide the Trustee and Securityholders with such annual reports and such information, documents
and other reports as are specified in Sections 13 and 15(d) of the Exchange Act and applicable to a U.S. corporation subject to such Sections, such information, documents and other reports to be so filed and provided at the times specified for the
filing of such information, documents and reports under such Sections. The Company also shall comply with the other provisions of TIA Section 314(a). 
 ARTICLE V 
 SUCCESSOR COMPANY 
 SECTION 5.01         WHEN COMPANY MAY MERGE OR TRANSFER ASSETS. 
 The Company shall not, while any of the Securities remain outstanding, consolidate or merge with or into any Person, or sell, lease, convey or otherwise
dispose of all or substantially all of its assets, or assign any of its obligations under this Indenture or any series of Securities, to any Person, unless: 
 (1)         the Person formed by or surviving such consolidation or merger (if other than the
Company), or to which such sale, lease, conveyance or other disposition or arrangement shall be made (collectively, the “Successor Company”), is a corporation organized and existing under the laws of the United States or any State thereof
or the District of Columbia and the Successor Company assumes by supplemental indenture in a form reasonably satisfactory to the Trustee all of the obligations of the Company under this Indenture and under the Securities; 
 (2)         immediately after giving effect to such transaction no Default shall have occurred
and be continuing; and 
  

 23 

 (3)         the Company shall have delivered to
the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that such consolidation, merger or transfer and such supplemental indenture (if any) comply with this Indenture. 
 The Successor Company shall be the successor to the Company and shall succeed to, and be substituted for, and may exercise every right and power of, the
Company under this Indenture, and the predecessor Company (except in the case of a lease) shall be released from the obligation to pay the principal of and interest on the Securities. 
 ARTICLE VI 
 DEFAULTS AND REMEDIES 
 SECTION 6.01         EVENTS OF DEFAULT. 
 An “Event of Default” occurs with respect to a series of Securities if: 
 (1)         the Company defaults in any payment of interest on any of the Securities of that
series when the same becomes due and payable and such default continues for a period of 30 days; 
 (2)
        the Company defaults in the payment of the principal of any of the Securities of that series when the same becomes due and payable at its Stated Maturity, upon optional redemption, upon declaration or
otherwise; 
 (3)         the Company fails to comply with Section 5.01;

 (4)         the Company fails to comply with any of its agreements in the
Securities of that series or this Indenture (other than those referred to in clauses (1), (2) or (3) above) and such failure continues for 90 days after the notice specified below; 
 (5)         any default or event of default under any Indebtedness of the Company or any of its
Subsidiaries (other than any Indebtedness of the Company or any Subsidiary to the seller of a business or asset incurred in connection with the purchase thereof) which default or event of default results in at least $50.0 million of aggregate
principal amount of such Indebtedness being declared due and payable prior to maturity (the “cross acceleration provision”); 
 (6)         failure by the Company or any of its Subsidiaries to pay at maturity or otherwise when due (after giving effect to any applicable grace period) at least $50.0
million aggregate principal amount of Indebtedness at any one time; 
 (7)
        the Company pursuant to or within the meaning of any Bankruptcy Law: 
 (A)
        commences a voluntary case; 
 (B)
        consents to the entry of an order for relief against it in an involuntary case; 
  

 24 

 (C)         consents to the appointment of a
Custodian of it or for any substantial part of its property; 
 (D)         makes a
general assignment for the benefit of its creditors; or 
 (E)         takes any
comparable action under any foreign laws relating to insolvency; or 
 (8)         a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 
 (A)
        is for relief against the Company in an involuntary case; 
 (B)
        appoints a Custodian of the Company or for any substantial part of its property; or 
 (C)         orders the winding up or liquidation of the Company; 
 or any similar relief is granted under
any foreign laws and the order, decree or relief remains unstayed and in effect for 60 days. 
 The foregoing shall constitute Events of
Default whatever the reason for any such Event of Default and whether it is voluntary or involuntary or is effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative
or governmental body. No Event of Default with respect to a single series of Securities issued hereunder (and under or pursuant to any Supplemental Indenture, Officers’ Certificate or Board Resolution) specific to such series shall constitute
an Event of Default with respect to any other series of Securities unless otherwise provided in this Indenture or any Supplemental Indenture, Officers’ Certificate or Board Resolution with respect to any other series of Securities. 

Notwithstanding the foregoing, a default under Section 6.01(4) shall not constitute an Event of Default until the Trustee or the Holders of at
least 25% in principal amount of the outstanding Securities of such series notify the Company of the default and the Company does not cure such default within the time specified in Section 6.01(4) after receipt of such notice. Such notice must
specify the default, demand that it be remedied and state that such notice is a “Notice of Default.” 
 The Company shall deliver
to the Trustee, promptly after the occurrence thereof, written notice in the form of an Officers’ Certificate of any Event of Default under clauses (3), (5), (6), (7) and (8) and, within 60 days after the occurrence thereof, written
notice of any event which with the giving of notice or the lapse of time would become an Event of Default under clause (4), its status and what action the Company is taking or proposes to take with respect thereto. 
 SECTION 6.02         ACCELERATION. 
 If an Event of Default (other than an Event of Default specified in Section 6.01(7) or (8)) occurs and is continuing, the Trustee by notice to the
Company, or the Holders of at least 25% in 

  

 25 

 
outstanding principal amount of the Securities of such series by notice to the Company and the Trustee, may declare the principal of and accrued and unpaid
interest on all the Securities of such series to be due and payable. Upon such a declaration, such principal and interest shall be due and payable immediately. If an Event of Default specified in Section 6.01(7) or (8) occurs, the
principal of and accrued and unpaid interest on all the Securities of such series shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holders. The Holders of a majority in
principal amount of the Securities of such series outstanding by notice to the Trustee may rescind an acceleration and its consequences if the rescission would not conflict with any judgment or decree and if all existing Events of Default have been
cured or waived except nonpayment of principal or interest that has become due solely because of acceleration. No such rescission shall affect any subsequent Default or Event of Default or impair any right consequent thereto. 
 SECTION 6.03         OTHER REMEDIES. 
 If an Event of Default occurs and is continuing with respect to a series of Securities, the Trustee may pursue any available remedy to collect the
payment of principal of or interest on the Securities of such series or to enforce the performance of any provision of the Securities of such series or this Indenture. 
 The Trustee may maintain a proceeding even if it does not possess any of the Securities of such series or does not produce any of them in the proceeding. A delay or omission by the Trustee or any Holder in exercising
any right or remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No remedy is exclusive of any other remedy. All available remedies are cumulative.

 SECTION 6.04         WAIVER OF PAST DEFAULTS. 
 The Holders of a majority in outstanding principal amount of the Securities of such series by notice to the Trustee may waive an existing Default and its
consequences except (i) a Default in the payment of the principal of or interest on a Security or (ii) a Default in respect of a provision that under Section 9.02 cannot be amended without the consent of each Holder affected. When a
Default is waived, it is deemed cured, but no such waiver shall extend to any subsequent or other Default or impair any consequent right. 
 SECTION 6.05         CONTROL BY MAJORITY. 
 The Holders of a majority in outstanding
principal amount of the Securities of such series may direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or of exercising any trust or power conferred on the Trustee. However, the Trustee may
refuse to follow any direction that conflicts with law or this Indenture or, subject to Section 7.01, that the Trustee reasonably determines is unduly prejudicial to the rights of other Holders or would involve the Trustee in personal
liability; provided, however, that the Trustee may take any other action deemed proper by the Trustee that is not inconsistent with such direction. Prior to taking any action hereunder, the Trustee shall be entitled to indemnification satisfactory
to it in its sole discretion against all losses and expenses caused by taking or not taking such action. 
  

 26 

 SECTION 6.06         LIMITATION ON SUITS. 
 Except to enforce the right to receive payment of principal or interest when due, no Holder of Securities of a particular series may pursue any remedy
with respect to this Indenture or the Securities of such series unless: 
 (1)         the Holder
gives to the Trustee written notice stating that an Event of Default is continuing; 
 (2)
        the Holders of at least 25% in outstanding principal amount of the Securities of such series make a written request to the Trustee to pursue the remedy; 
 (3)         such Holder or Holders offer to the Trustee reasonable security or indemnity satisfactory to it
against any loss, liability or expense; 
 (4)         the Trustee does not comply with the request
within 60 days after receipt of the request and the offer of security or indemnity; and 
 (5)
        the Holders of a majority in principal amount of the Securities of such series do not give the Trustee a direction inconsistent with the request during such 60-day period. 
 A Holder may not use this Indenture to prejudice the rights of another Holder or to obtain a preference or priority over another Holder. 
 SECTION 6.07         RIGHTS OF HOLDERS TO RECEIVE PAYMENT. 
 Notwithstanding any other provision of this Indenture, the right of any Holder to receive payment of principal of and interest on the Securities held by
such Holder, on or after the respective due dates expressed in the Securities, or to bring suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder.

 SECTION 6.08         COLLECTION SUIT BY TRUSTEE. 
 If an Event of Default specified in Section 6.01(1) or (2) occurs and is continuing, the Trustee may recover judgment in its own name and as
Trustee of an express trust against the Company for the whole amount then due and owing (together with interest on any unpaid interest to the extent lawful) and the amounts provided for in Section 7.07. 
 SECTION 6.09         TRUSTEE MAY FILE PROOFS OF CLAIM. 
 The Trustee may file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee and
the Holders allowed in any judicial proceedings relative to the Company, its Subsidiaries or their respective creditors or properties and, unless prohibited by law or applicable regulations, may vote on behalf of the Holders in any election of a
trustee in bankruptcy or other Person performing similar functions, and any Custodian in any such judicial proceeding is hereby authorized by each Holder to make payments to the Trustee and, in the event that the Trustee shall consent to the making
of such 

  

 27 

 
payments directly to the Holders, to pay to the Trustee any amount due it for the compensation, expenses, disbursements and advances of the Trustee, its
agents and its counsel, and any other amounts due the Trustee under Section 7.07. 
 SECTION 6.10
        PRIORITIES. 
 If the Trustee collects any money or property pursuant to this Article VI,
it shall pay out the money or property in the following order: 
 FIRST: to the Trustee for amounts due under Section 7.07; 

SECOND: to Holders for amounts due and unpaid on the Securities of such series for principal and interest, ratably, without preference or priority of
any kind, according to the amounts due and payable on the Securities of such series for principal and interest, respectively; and 
 THIRD:
to the Company. 
 Notwithstanding anything to the contrary in Section 2.03, the Trustee may fix a record date and payment date for any
payment to Holders pursuant to this Section 6.10. At least 15 days before such record date, the Company shall mail to each Holder and the Trustee a notice that states the record date, the payment date and amount to be paid. 
 SECTION 6.11         UNDERTAKING FOR COSTS. 
 In any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken or omitted by it as
Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys’ fees and
expenses, against any party litigant in the suit, having due regard to the merits and good faith of the claims or defenses made by the party litigant. This Section 6.11 does not apply to a suit by the Trustee, a suit by a Holder pursuant to
Section 6.07 or a suit by Holders of more than 10% in outstanding principal amount of the Securities of such series. 
 SECTION 6.12
        WAIVER OF STAY OR EXTENSION LAWS. 
 The Company (to the extent it may lawfully do so)
shall not at any time insist upon, or plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay or extension law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance
of this Indenture; and the Company (to the extent that it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and shall not hinder, delay or impede the execution of any power herein granted to the Trustee, but shall
suffer and permit the execution of every such power as though no such law had been enacted. 
  

 28 

 ARTICLE VII 
 CONCERNING THE TRUSTEE 
 SECTION 7.01         DUTIES OF
TRUSTEE. 
 (a)         If an Event of Default has occurred and is continuing, the Trustee shall
exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs. 

(b)         Except during the continuance of an Event of Default: 
 (1)         the Trustee undertakes to perform such duties and only such duties as are
specifically set forth in this Indenture and no implied covenants or obligations shall be read into this Indenture against the Trustee; and 
 (2)         in the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein,
upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture. However, in the case of certificates or opinions specifically required by any provision hereof to be furnished to it, the Trustee shall
examine the certificates and opinions to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of any mathematical calculations or other facts stated therein). 
 (c)         The Trustee may not be relieved from liability for its own negligent action, its own negligent
failure to act or its own willful misconduct, except that: 
 (1)         this
paragraph does not limit the effect of Section 7.01(b); 
 (2)         the
Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer unless it is proved that the Trustee was negligent in ascertaining the pertinent facts; and 
 (3)         the Trustee shall not be liable with respect to any action it takes or omits to take
in good faith in accordance with a direction received by it pursuant to Section 6.05. 
 (d)
        The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company. 
 (e)         Money held in trust by the Trustee need not be segregated from other funds except to the extent
required by law. 
 (f)         No provision of this Indenture shall require the Trustee to expend or
risk its own funds or otherwise incur financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers, if it shall have reasonable grounds to believe that 

  

 29 

 
repayment of such funds or adequate indemnity against such risk or liability is not reasonably assured to it. 
 (g)         Every provision of this Indenture relating to the conduct or affecting the liability of or affording
protection to the Trustee shall be subject to the provisions of this Section 7.01 and to the provisions of the TIA. 
 SECTION 7.02
        RIGHTS OF TRUSTEE. 
 (a)         The Trustee may
conclusively rely on any document (whether in original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document. 

(b)         Before the Trustee acts or refrains from acting, it may require an Officers’ Certificate or
an Opinion of Counsel. The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on the Officers’ Certificate or Opinion of Counsel. 
 (c)         The Trustee may act through its attorneys and agents and shall not be responsible for the willful
misconduct or negligence of any attorney or agent appointed with due care. 
 (d)         The Trustee
shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers; provided, however, that the Trustee’s conduct does not constitute willful misconduct or negligence.

 (e)         The Trustee may consult with counsel of its selection, and the advice or opinion of
counsel with respect to legal matters relating to this Indenture and the Securities shall be full and complete authorization and protection from liability in respect to any action taken, omitted or suffered by it hereunder in good faith and in
accordance with the advice or opinion of such counsel. 
 (f)         The Trustee shall be under no
obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders pursuant to this Indenture, unless such Holders shall have offered to the Trustee security or indemnity satisfactory
to the Trustee against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction. 
 (g)
        In no event shall the Trustee be responsible or liable for special, indirect, or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of
whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. 
 (h)
        The Trustee shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is
in fact such a default is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the Securities and this Indenture. 
 (i)         The rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be indemnified, are extended to, and
shall be 

  

 30 

 
enforceable by, the Trustee in each of its capacities hereunder, and each agent, custodian and other Person employed to act hereunder. 
 (j)         Any request or direction of the Company mentioned herein shall be sufficiently evidenced by a company
order and any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution. 
 (k)
        The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent,
order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall
determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by agent or attorney at the sole cost of the Company and shall incur no liability or additional
liability of any kind by reason of such inquiry or investigation. 
 SECTION 7.03
        INDIVIDUAL RIGHTS OF TRUSTEE. 
 The Trustee in its individual or any other capacity may
become the owner or pledgee of Securities and may otherwise deal with the Company or its Affiliates with the same rights it would have if it were not Trustee. Any Paying Agent, Registrar, co-registrar or co-paying agent may do the same with like
rights. However, the Trustee must comply with Sections 7.10 and 7.11. 
 SECTION 7.04
        TRUSTEE’S DISCLAIMER. 
 The Trustee shall not be responsible for and makes no
representation as to the validity or adequacy of this Indenture or the Securities, it shall not be accountable for the Company’s use of the proceeds from the Securities, it shall not be responsible for the use or application of any money
received by any Paying Agent (other than itself as Paying Agent), and it shall not be responsible for any statement in this Indenture or in any document issued in connection with the sale of the Securities or in the Securities other than the
Trustee’s certificate of authentication. 
 SECTION 7.05         NOTICE OF DEFAULTS. 

 If a Default or Event of Default occurs and is continuing and it is known to a Responsible Officer of the Trustee, the Trustee shall mail
to each Holder notice of the Default or Event of Default within 60 days after it occurs or promptly upon the Trustee’s attaining knowledge of such Default or Event of Default, whichever comes first. Except in the case of a Default or Event of
Default in payment of principal of, or interest on, any Security, the Trustee may withhold the notice if and so long as a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Holders.

 SECTION 7.06         REPORTS BY TRUSTEE TO HOLDERS. 
 As promptly as practicable after each May 15 beginning with the May 15 following the date of this Indenture, and in any event prior to July 15 in each
year, if required by TIA Section 313, the Trustee shall mail to each Holder a brief report dated as of such May 15 that complies 

  

 31 

 
with TIA Section 313(a). The Trustee also shall comply with TIA Section 313(b). The Trustee shall also transmit by mail all reports required by TIA
Section 313(c). 
 A copy of each report at the time of its mailing to Holders shall be filed by the Company with the Commission and
each stock exchange (if any) on which the Securities are listed. The Company agrees to notify promptly the Trustee whenever the Securities become listed on any stock exchange and of any delisting thereof. 
 SECTION 7.07         COMPENSATION AND INDEMNITY. 
 The Company shall pay to the Trustee from time to time, and the Trustee shall be entitled to, reasonable compensation for its services. The
Trustee’s compensation shall not be limited by any law on compensation of a Trustee of an express trust. The Company shall reimburse the Trustee upon request for all out-of-pocket expenses incurred or made by it, including costs of collection,
costs of preparing and reviewing reports, certificates and other documents, costs of preparation and mailing of notices to Holders and reasonable fees and expenses of counsel retained by the Trustee in addition to the compensation for its services.
Such expenses shall include the reasonable compensation and expenses, disbursements and advances of the Trustee’s agents, counsel, accountants and experts. The Company shall indemnify and hold harmless the Trustee against any and all loss,
liability, claim, damage or expense (including reasonable attorneys’ fees and expenses) incurred by it in connection with the administration of this trust and the performance of its duties hereunder, including the costs and expenses of
enforcing this Indenture (including this Section 7.07) and of defending itself against any claims (whether asserted by any Holder, the Company or otherwise). The Trustee, upon a Responsible Officer receiving written notice thereof, shall notify
the Company promptly of any claim for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder. The Company shall defend the claim and the Trustee may have separate
counsel and the Company shall pay the fees and expenses of such counsel. The Company need not reimburse any expense or indemnify against any loss, liability or expense incurred by the Trustee through the Trustee’s own willful misconduct,
negligence or bad faith. 
 To secure the Company’s payment obligations in this Section 7.07, the Trustee shall have a Lien prior
to the Securities on all money or property held or collected by the Trustee other than money or property held in trust to pay principal of and interest on particular Securities. The Trustee’s right to receive payment of any amounts due under
this Section 7.07 shall not be subordinate to any other liability or indebtedness of the Company. 
 The Company’s payment
obligations pursuant to this Section 7.07 shall survive the discharge of this Indenture and the resignation or removal of the Trustee. When the Trustee incurs expenses after the occurrence of a Default specified in Section 6.01(7) or
(8) with respect to the Company, the expenses are intended to constitute expenses of administration under any Bankruptcy Law. 
 SECTION 7.08         REPLACEMENT OF TRUSTEE. 
 The Trustee may resign at any time by
so notifying the Company. The Holders of a majority in outstanding principal amount of the Securities of a series may remove the Trustee by 

  

 32 

 
so notifying the Trustee and may appoint a successor Trustee as to such series. The Company shall remove the Trustee if: 
 (1)         the Trustee fails to comply with Section 7.10; 
 (2)         the Trustee is adjudged bankrupt or insolvent; 
 (3)         a receiver or other public officer takes charge of the Trustee or its property; or

 (4)         the Trustee otherwise becomes incapable of acting. 
 If the Trustee resigns, is removed by the Company, is removed by the Holders of a majority in outstanding principal amount of the Securities of a series
and such Holders do not reasonably promptly appoint a successor Trustee, or if a vacancy exists in the office of Trustee for any reason (the Trustee in such event being referred to herein as the retiring Trustee), the Company shall promptly appoint
a successor Trustee. 
 A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company.
Thereupon the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee under this Indenture. The successor Trustee shall mail a notice of its
succession to the Securityholders. The retiring Trustee shall (upon payment of its charges) promptly transfer all property held by it as Trustee to the successor Trustee, subject to the Lien provided for in Section 7.07. 
 If a successor Trustee does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee or the Holders of 10%
in outstanding principal amount of the Securities of a series at the expense of the Company may petition any court of competent jurisdiction for the appointment of a successor Trustee. 
 If the Trustee fails to comply with Section 7.10, any Securityholder may petition any court of competent jurisdiction for the removal of the Trustee
and the appointment of a successor Trustee. 
 Notwithstanding the replacement of the Trustee pursuant to this Section 7.08, the
Company’s obligations under Section 7.07 shall continue for the benefit of the retiring Trustee. 
 SECTION 7.09
        SUCCESSOR TRUSTEE BY MERGER. 
 If the Trustee consolidates with, merges or converts
into, or transfers all or substantially all its corporate trust business or assets to, another corporation or banking association, the resulting, surviving or transferee corporation or banking association without any further act shall be the
successor Trustee. 
 If at the time such successor or successors by merger, conversion or consolidation to the Trustee shall succeed to the
trusts created by this Indenture, any of the Securities of a series shall have been authenticated but not delivered, any such successor to the Trustee may adopt the 

  

 33 

 
certificate of authentication of any predecessor Trustee, and deliver such Securities so authenticated; and if at that time any of the Securities of a series
shall not have been authenticated, any successor to the Trustee may authenticate such Securities either in the name of any predecessor hereunder or in the name of the successor to the Trustee; and in all such cases such certificates shall have the
full force which it is anywhere in the Securities of a series or in this Indenture provided that the certificate of the Trustee shall have. 
 SECTION 7.10         ELIGIBILITY; DISQUALIFICATION. 
 The Trustee shall at all times
satisfy the requirements of TIA Section 310(a). The Trustee shall have a combined capital and surplus of at least $50 million as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA
Section 310(b); provided, however, that there shall be excluded from the operation of TIA Section 310(b)(1) any indenture or indentures under which other securities or certificates of interest or participation in other securities of the
Company are outstanding if the requirements for such exclusion set forth in TIA Section 310(b)(1) are met. 
 SECTION 7.11
        PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY. 
 The Trustee shall comply with TIA
Section 311(a), excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section 311(a) to the extent indicated. 
 ARTICLE VIII 
 CONCERNING THE
SECURITYHOLDERS 
 SECTION 8.01         EVIDENCE OF ACTION BY SECURITYHOLDERS. 

Whenever in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the Securities of a
particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders of such majority or
specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that series in Person or by agent or proxy appointed in writing. If
the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice, consent, waiver or other action, the Company may, at its option, as evidenced by an Officers’ Certificate, fix in advance a
record date for such series for the determination of Securityholders entitled to give such request, demand, authorization, direction, notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date
is fixed, such request, demand, authorization, direction, notice, consent, waiver or other action may be given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be
Securityholders for the purposes of determining whether Securityholders of the requisite proportion of outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, 

  

 34 

 
notice, consent, waiver or other action, and for that purpose the outstanding Securities of that series shall be computed as of the record date; provided,
however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later than six months after the record
date. 
 SECTION 8.02         PROOF OF EXECUTION BY SECURITYHOLDERS. 
 Subject to the provisions of Section 7.01, proof of the execution of any instrument by a Securityholder (such proof will not require notarization)
or his agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner: 
 (a)         The fact and date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee. 
 (b)         The ownership of Securities shall be proved by the Security Register of such Securities or by a
certificate of the Security Registrar thereof. 
 (c)         The Trustee may require such additional
proof of any matter referred to in this Section as it shall deem necessary. 
 SECTION 8.03
        WHO MAY BE DEEMED OWNERS. 
 Prior to the due presentment for registration of transfer of
any Security, the Company, the Trustee, any paying agent and any Security Registrar may deem and treat the Person in whose name such Security shall be registered upon the books of the Company as the absolute owner of such Security (whether or not
such Security shall be overdue and notwithstanding any notice of ownership or writing thereon made by anyone other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of (and premium, if any) and
(subject to Section 2.03) interest on such Security and for all other purposes; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar shall be affected by any notice to the contrary. 
 SECTION 8.04         CERTAIN SECURITIES OWNED BY COMPANY DISREGARDED. 
 In determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any direction,
consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common control
with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be outstanding for the purpose of any such determination, except that for the purpose of determining whether the Trustee shall be protected
in relying on any such direction, consent or waiver, only Securities of such series that a Responsible Officer of the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in good faith may be
regarded as outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the Trustee the pledgee’s right so to act with 

  

 35 

 
respect to such Securities and that the pledgee is not a Person directly or indirectly controlling or controlled by or under direct or indirect common
control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. Also, subject to the foregoing, only Securities of a
series outstanding at the time shall be considered in any such determination. 
 SECTION 8.05
        ACTIONS BINDING ON FUTURE SECURITYHOLDERS. 
 At any time prior to (but not after) the
evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection
with such action, any holder of a Security of that series that is shown by the evidence to be included in the Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as
provided in Section 8.02, revoke such action so far as concerns such Security. Except as aforesaid any such action taken by the holder of any Security shall be conclusive and binding upon such holder and upon all future holders and owners of
such Security, and of any Security issued in exchange therefor, on registration of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made upon such Security. Any action taken by the holders of the
majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the
Securities of that series. 
 ARTICLE IX 
 SUPPLEMENTAL INDENTURES 
 SECTION 9.01
        SUPPLEMENTAL INDENTURES WITHOUT THE CONSENT OF SECURITYHOLDERS. 
 In addition to any
supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture
Act as then in effect), without the consent of the Securityholders, for one or more of the following purposes: 
 (1)
        to cure any ambiguity, defect, or inconsistency herein, or in the Securities of any series; 
 (2)         to comply with Article V; 
 (3)
        to provide for uncertificated Securities in addition to or in place of certificated Securities; 
 (4)         to add to the covenants of the Company for the benefit of the holders of all or any series of Securities (and if such covenants are to be for the benefit of less
than all series of Securities, stating that such covenants are expressly being included solely for the benefit of such series) or to surrender any right or power herein conferred upon the 

  

 36 

 
Company or to add any additional Events of Default for the benefit of the holders of all or any series of Securities (and if such additional Events of
Default are to be for the benefit of less than all series of Securities, stating that such additional Events of Default are expressly being included solely for the benefit of such series) or to add guarantees with respect to any series of
Securities; 
 (5)         to make any change that does not adversely affect the
rights of any Securityholder in any material respect; 
 (6)         to provide for
the issuance of and establish the form and terms and conditions of the Securities of any series as provided in Section 2.01, to establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any
series of Securities, or to add to the rights of the holders of any series of Securities; or 
 (7)
        to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more series and to add to or change any of the provisions of this
Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, pursuant to the requirements of Section 7.08. 
 The Trustee is hereby authorized to join with the Company in the execution of any such supplemental indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the
Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise. 
 Any supplemental indenture authorized by the provisions of this Section may be executed by the Company and the Trustee without the consent of the holders
of any of the Securities at the time outstanding, notwithstanding any of the provisions of Section 9.02. 
 SECTION 9.02
        SUPPLEMENTAL INDENTURES WITH CONSENT OF SECURITYHOLDERS. 
 With the consent (evidenced
as provided in Section 8.01) of the holders of not less than a majority in aggregate principal amount of the Securities of each series affected by such supplemental indenture or indentures at the time outstanding, the Company, when authorized
by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any
provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner not covered by Section 9.01 the rights of the holders of the Securities of such series
under this Indenture; provided, however, that no such supplemental indenture shall, without the consent of the holders of each Security then outstanding and affected thereby: 
 (1)         change the maturity of the principal of, or any installment of principal of or
interest on, any Security, or reduce the principal amount thereof or the rate of interest 

  

 37 

 
thereon or any premium payable upon the redemption thereof, or reduce the amount of the principal of an Original Issue Discount Security or any other
Security which would be due and payable upon a declaration of acceleration of the maturity thereof pursuant to Section 6.01 or change the coin or currency in which any Security or any premium or interest thereon is payable, or impair the right
to institute suit for the enforcement of any such payment on or after the maturity thereof (or, in the case of redemption, on or after the redemption date), or 
 (2)         reduce the percentage in principal amount of the outstanding Securities of any
series, the consent of whose holders is required for any such supplemental indenture, or the consent of whose holders is required for any waiver of certain defaults hereunder and their consequences provided for in this Indenture, or 
 (3)         modify any of the provisions of this Section or Section 6.04 relating to waivers
of default, except to increase any such percentage or to provide that certain other provisions of this Indenture cannot be modified or waived without the consent of the holder of each outstanding Security affected thereby; provided, however, that
this clause shall not be deemed to require the consent of any holder with respect to changes in the references to “the Trustee” and concomitant changes in this Section, or the deletion of this proviso, in accordance with the requirements
of Sections 7.08 and 9.01(8). 
 A supplemental indenture which changes or eliminates any covenant or other provision of this Indenture which
has expressly been included solely for the benefit of one or more particular series of Securities, or which modifies the rights of the holders of Securities of such series with respect to such covenant or other provision, shall be deemed not to
affect the rights under this Indenture of the holders of Securities of any other series. It shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular form of any
proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof. 
 SECTION 9.03
        EFFECT OF SUPPLEMENTAL INDENTURES. 
 Upon the execution of any supplemental indenture
pursuant to the provisions of this Article, this Indenture shall, with respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities
under this Indenture of the Trustee, the Company and the holders of Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the
terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms and conditions of this Indenture for any and all purposes. 
 SECTION 9.04         SECURITIES AFFECTED BY SUPPLEMENTAL INDENTURES. 
 Securities of any series, affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture pursuant to the provisions of this Article, may bear a notation in form approved by the Company,
provided such form meets the 

  

 38 

 
requirements of any exchange upon which such series may be listed, as to any matter provided for in such supplemental indenture. If the Company shall so
determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors of the Company, to any modification of this Indenture contained in any such supplemental indenture may be prepared by the Company,
authenticated by the Trustee and delivered in exchange for the Securities of that series then outstanding. 
 SECTION 9.05
        EXECUTION OF SUPPLEMENTAL INDENTURES. 
 Upon the request of the Company, accompanied by
its Board Resolutions authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company
in the execution of such supplemental indenture unless such supplemental indenture affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be
obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of Section 7.01, shall be provided with an Opinion of Counsel and Officers’ Certificate as conclusive evidence that any supplemental indenture
executed pursuant to this Article is authorized or permitted by, and conforms to, the terms of this Article and that it is proper for the Trustee under the provisions of this Article to join in the execution thereof; provided, however, that such
Opinion of Counsel and Officers’ Certificate need not be provided in connection with the execution of a supplemental indenture that establishes the terms of a series of Securities pursuant to Section 2.01 hereof. 
 Promptly after the execution by the Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Trustee shall
transmit at the expense of the Company by mail, first class postage prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to the Securityholders of all series affected thereby as their names and addresses
appear upon the Security Register. Any failure of the Trustee to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture. 
 SECTION 9.06         PAYMENT FOR CONSENT 
 Neither the Company nor any Affiliate of the Company shall, directly or indirectly, pay or cause to be paid any consideration, whether by way of
interest, fee or otherwise, to any Holder for or as an inducement to any consent, waiver or amendment of any of the terms or provisions of the Securities of a series or this Indenture with respect to the Securities of a series unless such
consideration is offered to be paid to all Holders of a series of Securities that so consent, waive or agree to amend in the time frame set forth in solicitation documents relating to such consent, waiver or agreement. 
  

 39 

 ARTICLE X 
 SATISFACTION AND DISCHARGE; DEFEASANCE 
 SECTION 10.01
        SATISFACTION AND DISCHARGE. 
 This Indenture will be discharged and will cease to be of
further effect with respect to a series of Securities (except as to any surviving rights of registration of transfer or exchange of such series of Securities herein expressly provided for), and the Trustee, at the expense of the Company, shall
execute proper instruments acknowledging satisfaction and discharge of this Indenture with respect to such series, when: 
 (1)         either (A) all Securities of that series theretofore authenticated and delivered (other than (i) any Securities that shall have been destroyed, lost or stolen and that shall have
been replaced or paid as provided in Section 2.07 and (ii) Securities for whose payment money or noncallable Governmental Obligations have theretofore been deposited in trust or segregated and held in trust by the Company and thereafter
repaid to the Company or discharged from such trust, as provided in Section 10.05) have been delivered to the Trustee for cancellation; or (B) all Securities of such series not theretofore delivered to the Trustee for cancellation
(i) have become due and payable, or (ii) will by their terms become due and payable within one year, or (iii) are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of
redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds in trust for such purpose (x) moneys in an amount, or (y) noncallable Governmental Obligations the scheduled principal of and interest on
which in accordance with their terms will provide, not later than the due date of any payment, money in an amount, or (z) a combination thereof, sufficient, in the case of (y) or (z), in the opinion of a nationally recognized firm of
independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay and discharge, at maturity or upon redemption, all Securities of that series not theretofore delivered to the Trustee for cancellation,
including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be; 
 (2)         the Company has paid or caused to be paid all other sums payable hereunder with respect to such series by the Company; and 
 (3)         the Company has delivered to the Trustee an Officers’ Certificate and an Opinion
of Counsel, each stating that all the conditions precedent herein provided for relating to the satisfaction and discharge of this Indenture with respect to such series of Securities have been complied with. Notwithstanding the satisfaction and
discharge of this Indenture with respect to a series of Securities, the obligations of the Trustee under Section 7.07 and, if money and or securities shall have been deposited with the Trustee pursuant to subclause (iii) of clause
(1) of this Section, the obligations of the Trustee under Sections 10.04 and 10.05 shall survive such satisfaction and discharge. 
  

 40 

 SECTION 10.02         DEFEASANCE. 
 (a)         Subject to Sections 10.02(b) and 10.03, the Company at any time may terminate (1) all of its
obligations under a particular series of Securities and under this Indenture with respect to that series of Securities (“legal defeasance option”) or (2) with respect to a particular series of Securities, its obligations under
Sections 4.06, 4.07 and 4.08 (“covenant defeasance option”); provided, however, no deposit under this Article X shall be effective to terminate the obligations of the Company under a series of Securities or this Indenture with respect to
that series of Securities prior to 91 days following any such deposit. The Company may exercise its legal defeasance option notwithstanding its prior exercise of its covenant defeasance option. 
 If the Company exercises its legal defeasance option, payment of the Securities may not be accelerated because of an Event of Default. If the Company
exercises its covenant defeasance option, payment of the Securities may not be accelerated because of an Event of Default specified in Sections 6.01(4) due to a violation of Sections 4.06, 4.07 and 4.08. 
 Upon satisfaction of the conditions set forth herein and upon request of the Company, the Trustee shall acknowledge in writing the discharge of those
obligations that the Company terminates. 
 (b)         The Company’s obligations in Sections
2.05, 2.06, 2.07, 7.07 and 7.08 and this Article X shall survive until the Securities have been paid in full. Thereafter, the Company’s obligations in Sections 7.07 and 10.05 shall survive. 
 SECTION 10.03         CONDITIONS TO DEFEASANCE. 
 The Company may exercise its legal defeasance option or its covenant defeasance option with respect to a series of Securities only if: 
 (1)         the Company irrevocably deposits in trust with the Trustee money or Governmental
Obligations for the payment of principal of and interest on that series of the Securities to Stated Maturity or redemption, as the case may be; 
 (2)         the Company delivers to the Trustee a certificate from a nationally recognized firm of independent accountants expressing their opinion that the payments of
principal and interest when due and without reinvestment on the deposited Governmental Obligations plus any deposited money without reinvestment will provide cash at such times and in such amounts as will be sufficient to pay principal and interest
when due on all the Securities of that series to Stated Maturity or redemption, as the case may be; 
 (3)
        91 days pass after the deposit is made and during the 91-day period no Default specified in Sections 6.01(7) or (8) occurs which is continuing at the end of the periods; 
 (4)         the deposit does not constitute a default under any other agreement binding on the
Company; 
  

 41 

 (5)         the Company delivers to the Trustee
an Opinion of Counsel to the effect that the trust resulting from the deposit does not constitute, or is qualified as, a regulated investment company under the Investment Company Act of 1940; 
 (6)         in the case of the legal defeasance option, the Company shall have delivered to the
Trustee an Opinion of Counsel stating that (A) the Company has received from, or there has been published by, the Internal Revenue Service a ruling, or (B) since the date of this Indenture there has been a change in the applicable Federal
income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Securityholders will not recognize income, gain or loss for Federal income tax purposes as a result of such defeasance and will be
subject to Federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such legal defeasance had not occurred; 
 (7)         in the case of the covenant defeasance option, the Company shall have delivered to
the Trustee an Opinion of Counsel to the effect that the Securityholders shall not recognize income, gain or loss for Federal income tax purposes as a result of such covenant defeasance and shall be subject to Federal income tax on the same amounts,
in the same manner and at the same times as would have been the case if such covenant defeasance had not occurred; 
 (8)
        the Securityholders shall have a perfected security interest under applicable law in the cash or Governmental Obligations deposited pursuant to Section 10.03(1) above; 
 (9)         the Company shall have delivered to the Trustee an Opinion of Counsel, in form and
substance reasonably satisfactory to the Trustee, to the effect that, after the passage of 91 days following the deposit, the trust funds shall not be subject to any applicable bankruptcy, insolvency, reorganization or similar law affecting
creditors’ rights generally; 
 (10)       such defeasance shall not cause the Trustee to
have a conflicting interest with respect to any securities of the Company; and 
 (11)
      the Company delivers to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent to the defeasance and discharge of the Securities and this Indenture as
contemplated by this Article X have been complied with. 
 Before or after a deposit, the Company may make arrangements satisfactory to the
Trustee for the redemption of Securities at a future date in accordance with Article III. 
 SECTION 10.04
        APPLICATION OF TRUST MONEY. 
 The Trustee shall hold in trust money or Governmental
Obligations deposited with it pursuant to this Article X. It shall apply the deposited money and the money from Governmental Obligations through the Paying Agent and in accordance with this Indenture to the payment of principal of and interest on
the Securities. 
  

 42 

 SECTION 10.05         REPAYMENT TO COMPANY. 
 The Trustee and the Paying Agent shall promptly turn over to the Company upon request any excess money or securities held by them on account of any
series of Securities in accordance with this Article X upon payment of all principal of and interest on the Securities of that series. Subject to any applicable abandoned property law, the Trustee and the Paying Agent shall pay to the Company upon
request any money held by them for the payment of principal of or interest on the Securities that remains unclaimed for two years, and, thereafter, Securityholders entitled to the money must look to the Company for payment as general creditors.

 SECTION 10.06         INDEMNITY FOR GOVERNMENTAL OBLIGATIONS. 
 The Company shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on or assessed against deposited Governmental
Obligations or the principal and interest received on such Governmental Obligations. 
 SECTION 10.07
        REINSTATEMENT. 
 If the Trustee or Paying Agent is unable to apply any money or
Governmental Obligations in accordance with this Article X by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the
obligations of the Company under this Indenture and the Securities shall be revived and reinstated as though no deposit had occurred pursuant to this Article X until such time as the Trustee or Paying Agent is permitted to apply all such money or
Governmental Obligations in accordance with this Article X; provided, however, that, if the Company has made any payment of interest on or principal of any Securities because of the reinstatement of its obligations, the Company shall be subrogated
to the rights of the Holders of such Securities to receive such payment from the money or Governmental Obligations held by the Trustee or Paying Agent. 
 ARTICLE XI 
 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, 
 OFFICERS AND DIRECTORS 
 SECTION
11.01         NO RECOURSE. 
 No recourse under or upon any obligation, covenant or agreement of
this Indenture, or of any Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or
successor corporation, either directly or through the Company or any such predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being
expressly understood that this Indenture and the obligations issued hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or
directors as such, of the Company or of any predecessor or successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained 

  

 43 

 
in this Indenture or in any of the Securities or implied therefrom; and that any and all such personal liability of every name and nature, either at common
law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as such, because of the creation of the indebtedness hereby authorized, or under or by
reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture
and the issuance of such Securities. 
 ARTICLE XII 
 MISCELLANEOUS PROVISIONS 
 SECTION 12.01         EFFECT ON
SUCCESSORS AND ASSIGNS. 
 All the covenants, stipulations, promises and agreements in this Indenture contained by or on behalf of the
Company shall bind its successors and assigns, whether so expressed or not. 
 SECTION 12.02
        ACTIONS BY SUCCESSOR. 
 Any act or proceeding by any provision of this Indenture
authorized or required to be done or performed by any board, committee or officer of the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the
time be the lawful successor of the Company. 
 SECTION 12.03         SURRENDER OF COMPANY POWERS.

 The Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of
the powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor corporation. 
 SECTION 12.04         NOTICES. 
 Except as otherwise
expressly provided herein any notice, instruction, request or demand that by any provision of this Indenture is required or permitted to be given or served by the Trustee or by the holders of Securities to or on the Company may be given or served by
being deposited first class postage prepaid in a post-office letterbox addressed (until another address is filed in writing by the Company with the Trustee), as follows: 358 South Main Street, Burlington, North Carolina 27215. Any notice, election,
request or demand by the Company or any Securityholder to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee. 
 SECTION 12.05         GOVERNING LAW. 
 This Indenture and each Security shall be deemed to be a contract made under the internal laws of the State of New York, and for all purposes shall be
construed in accordance with the laws of said State, but without giving effect to the applicable principles of conflicts of 

  

 44 

 
law to the extent that the application of the laws of another jurisdiction would be required thereby. 
 SECTION 12.06         TREATMENT OF SECURITIES AS DEBT. 
 It is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this Indenture
shall be interpreted to further this intention. 
 SECTION 12.07         COMPLIANCE CERTIFICATES
AND OPINIONS. 
 (a)         Upon any application or demand by the Company to the Trustee to take
any action under any of the provisions of this Indenture, the Company, shall furnish to the Trustee an Officers’ Certificate stating that all conditions precedent provided for in this Indenture relating to the proposed action have been complied
with and an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing of such documents is specifically
required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished. 
 (b)         Each certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or covenant in this Indenture
shall include 
 (i)         a statement that the Person making such certificate or
opinion has read such covenant or condition; 
 (ii)        a brief statement as to the
nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; 
 (iii)       a statement that, in the opinion of such Person, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or
not such covenant or condition has been complied with; and 
 (iv)       a statement as to
whether or not, in the opinion of such Person, such condition or covenant has been complied with. 
 SECTION 12.08
        PAYMENTS ON BUSINESS DAYS. 
 Except as provided pursuant to Section 2.01 pursuant
to a Board Resolution, pursuant to an Officers’ Certificate, or pursuant to one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any
Security shall not be a Business Day, then payment of interest or principal (and premium, if any) may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no
interest shall accrue for the period after such nominal date. 
  

 45 

 SECTION 12.09         CONFLICT WITH TRUST INDENTURE ACT. 

 If and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Sections 310 to 317,
inclusive, of the Trust Indenture Act, such imposed duties shall control. If any provision of this Indenture modifies or excludes any provision of the Trust Indenture Act which may be so modified or excluded, the latter provision shall be deemed to
apply to this Indenture as so modified or to be excluded, as the case may be. 
 SECTION 12.10
        COUNTERPARTS. 
 This Indenture may be executed in any number of counterparts, each of
which shall be an original, but such counterparts shall together constitute but one and the same instrument. 
 SECTION 12.11
        SEPARABILITY. 
 In case any one or more of the provisions contained in this Indenture or
in the Securities of any series shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities, but
this Indenture and such Securities shall be construed as if such invalid or illegal or unenforceable provision had never been contained herein or therein. 
 SECTION 12.12         ASSIGNMENT. 
 The Company will have the
right at all times to assign any of its rights or obligations under this Indenture to a direct or indirect wholly-owned Subsidiary of the Company, provided that, in the event of any such assignment, the Company, will remain liable for all such
obligations. Subject to the foregoing, the Indenture is binding upon and inures to the benefit of the parties thereto and their respective successors and assigns. This Indenture may not otherwise be assigned by the parties thereto. 
 SECTION 12.13         WAIVER OF JURY TRIAL. 
 EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN
ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTION CONTEMPLATED HEREBY. 
 SECTION 12.14
        FORCE MAJEURE. 
 In no event shall the Trustee be responsible or liable for any failure
or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military
disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which
are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 
  

 46 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed all as of the day
and year first above written. 
  

	
	 LABORATORY CORPORATION OF AMERICA
 HOLDINGS

	
	 By:
  

	  
 Name:
  

	  
 Title:
  

	
	 THE BANK OF NEW YORK MELLON TRUST
 COMPANY, N.A., as Trustee

	
	 By:
  

	  
 Name:
  

	  
 Title:
  

	
	  

  

 47 

 ANNEX A 
 [FORM OF SUPPLEMENTAL INDENTURE TO BE DELIVERED BY SUBSIDIARY GUARANTORS] 
 SUPPLEMENTAL INDENTURE
(this “Supplemental Indenture”), dated as of [                    ] among
[                    ] (the “Subsidiary Guarantor”), a
[                    ] corporation and a subsidiary of Laboratory Corporation of America Holdings, a Delaware corporation (or its permitted
successor) (the “Company”), the Company, [other Subsidiary Guarantors] and The Bank of New York Mellon Trust Company, N.A., as Trustee under the Indenture (the “Trustee”). 
 W I T N E S S E T H 
 WHEREAS, the Company has heretofore executed and delivered to the
Trustee an indenture (the “Indenture”), dated as of [                    ],
[                    ], providing for the issuance of a series of its senior debt securities designated as the
[                ] (the “Securities”); 
 WHEREAS,
in its discretion, the Company may have the Subsidiary Guarantor to execute and deliver to the Trustee a Guaranty Agreement pursuant to which the Subsidiary Guarantor will Guarantee payment of the Securities; and 
 WHEREAS, pursuant to Section 9.01(4) of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture. 
 NOW THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt of which is hereby acknowledged, the Company, the
Subsidiary Guarantor[, the other Subsidiary Guarantors] and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows: 
 SECTION 1. Capitalized Terms. Capitalized terms used herein but not defined shall have the meanings assigned to them in the Indenture. 
 SECTION 2. Guaranties. The Subsidiary Guarantor hereby unconditionally and irrevocably guarantees[, jointly and severally with the other Guarantors], to
each Holder and to the Trustee and its successors and assigns (a) the full and punctual payment of principal of and interest on the Securities when due, whether at maturity, by acceleration, by redemption or otherwise, and all other monetary
obligations of the Company under the Indenture and the Securities and (b) the full and punctual performance within applicable grace periods of all other obligations of the Company under the Indenture and the Securities (all the foregoing being
hereinafter collectively called the “Obligations”). 
 The Subsidiary Guarantor further agrees that the Obligations may be extended
or renewed, in whole or in part, without notice to or further assent from the Subsidiary Guarantor and that the Subsidiary Guarantor will remain bound under this Supplemental Indenture notwithstanding any extension or renewal of any Obligation.

 The Subsidiary Guarantor waives presentation to, demand of, payment from and protest to the Company of any of the Obligations and also
waives notice of protest for nonpayment. The 

  

 48 

 
Subsidiary Guarantor waives notice of any default under the Securities or the Obligations. The obligations of the Subsidiary Guarantor hereunder shall not be
affected by (a) the failure of any Holder or the Trustee to assert any claim or demand or to enforce any right or remedy against the Company or any other Person under the Indenture, this Supplemental Indenture, the Securities or any other
agreement or otherwise; (b) any extension or renewal of any thereof; (c) any rescission, waiver, amendment or modification of any of the terms or provisions of the Indenture, this Supplemental Indenture, the Securities or any other
agreement; (d) the release of any security held by any Holder or the Trustee for the Obligations or any of them; (e) the failure of any Holder or the Trustee to exercise any right or remedy against any other guarantor of the Obligations;
or (f) except as set forth in Section 7 of this Supplemental Indenture, any change in the ownership of the Subsidiary Guarantor. 
 The Subsidiary Guarantor further agrees that its guaranty herein constitutes a guarantee of payment, performance and compliance when due (and not a guarantee of collection) and waives any right to require that any resort be had by any
Holder or the Trustee to any security held for payment of the Obligations. 
 Except as expressly set forth in Section 10.02 of the
Indenture and Sections 3 and 7 of this Supplemental Indenture, the obligations of the Subsidiary Guarantor hereunder shall not be subject to any reduction, limitation, impairment or termination for any reason, including any claim of waiver, release,
surrender, alteration or compromise, and shall not be subject to any defense of setoff, counterclaim, recoupment or termination whatsoever or by reason of the invalidity, illegality or unenforceability of the Obligations or otherwise. Without
limiting the generality of the foregoing, the obligations of the Subsidiary Guarantor herein shall not be discharged or impaired or otherwise affected by the failure of any Holder or the Trustee to assert any claim or demand or to enforce any remedy
under the Indenture, this Supplemental Indenture, the Securities or any other agreement, by any waiver or modification of any provision thereof, by any default, failure or delay, willful or otherwise, in the performance of the Obligations, or by any
other act or thing or omission or delay to do any other act or thing which may or might in any manner or to any extent vary the risk of the Subsidiary Guarantor or would otherwise operate as a discharge of the Subsidiary Guarantor as a matter of law
or equity. 
 The Subsidiary Guarantor further agrees that its guaranty herein shall continue to be effective or be reinstated, as the case
may be, if at any time payment, or any part thereof, of principal of or interest on any Obligation is rescinded or must otherwise be restored by any Holder or the Trustee upon the bankruptcy or reorganization of the Company or otherwise. 

In furtherance of the foregoing and not in limitation of any other right which any Holder or the Trustee has at law or in equity against the
Subsidiary Guarantor by virtue hereof, upon the failure of the Company to pay the principal of or interest on any Obligation when and as the same shall become due, whether at maturity, by acceleration, by redemption or otherwise, or to perform or
comply with any other Obligation, the Subsidiary Guarantor hereby promises to and shall, upon receipt of written demand by the Trustee, forthwith pay, or cause to be paid, in cash, to the Holders or the Trustee an amount equal to the sum of
(1) the unpaid amount of such Obligations, (2) accrued and unpaid interest on such Obligations (but only to the extent not prohibited by law) and (3) all other monetary Obligations of the Company to the Holders and the Trustee.

  

 49 

 The Subsidiary Guarantor agrees that, as between it, on the one hand, and the Holders and the Trustee, on
the other hand, (x) the maturity of the Obligations guaranteed hereby may be accelerated as provided in Article VI of the Indenture for the purposes of the Subsidiary Guarantor’s guaranty herein, notwithstanding any stay, injunction or
other prohibition preventing such acceleration in respect of the Obligations guaranteed hereby, and (y) in the event of any declaration of acceleration of such Obligations as provided in Article VI of the Indenture, such Obligations (whether or
not due and payable) shall forthwith become due and payable by the Subsidiary Guarantor for the purposes of this Supplemental Indenture. 
 The Subsidiary Guarantor also agrees to pay any and all costs and expenses (including reasonable attorneys’ fees) incurred by the Trustee or any Holder in enforcing any rights under this Section 2. 
 SECTION 3. Limitation on Liability. Any term or provision of this Supplemental Indenture to the contrary notwithstanding, the maximum aggregate amount of
the Obligations guaranteed hereunder by the Subsidiary Guarantor shall not exceed the maximum amount that can be hereby guaranteed without rendering this Supplemental Indenture, as it relates to the Subsidiary Guarantor, voidable under applicable
law relating to fraudulent conveyance, fraudulent transfer or similar laws affecting the rights of creditors generally. 
 SECTION 4.
Successors and Assigns. This Supplemental Indenture shall be binding upon the Subsidiary Guarantor and its successors and assigns and shall inure to the benefit of the successors and assigns of the Trustee and the Holders and, in the event of any
transfer or assignment of rights by any 
 Holder or the Trustee, the rights and privileges conferred upon that party in this Supplemental
Indenture and in the Securities shall automatically extend to and be vested in such transferee or assignee, all subject to the terms and conditions of this Supplemental Indenture. 
 SECTION 5. No Waiver. Neither a failure nor a delay on the part of either the Trustee or the Holders in exercising any right, power or privilege under
this Supplemental Indenture shall operate as a waiver thereof, nor shall a single or partial exercise thereof preclude any other or further exercise of any right, power or privilege. The rights, remedies and benefits of the Trustee and the Holders
herein expressly specified are cumulative and not exclusive of any other rights, remedies or benefits which either may have under this Supplemental Indenture at law, in equity, by statute or otherwise. 
 SECTION 6. Modification. No modification, amendment or waiver of any provision of this Supplemental Indenture, nor the consent to any departure by the
Subsidiary Guarantor therefrom, shall in any event be effective unless the same shall be in writing and signed by the Trustee, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No
notice to or demand on the Subsidiary Guarantor in any case shall entitle the Subsidiary Guarantor to any other or further notice or demand in the same, similar or other circumstances. 
 SECTION 7. Release. Upon the sale or other disposition (including by way of consolidation or merger) of the Subsidiary Guarantor or the sale or
disposition of all or 

  

 50 

 
substantially all the assets of the Subsidiary Guarantor (in each case other than a sale or disposition to the Company or an affiliate of the Company), the
Subsidiary Guarantor shall be deemed released from all obligations under this Supplemental Indenture without any further action required on the part of the Trustee or any Holder. At the request and expense of the Company, the Trustee shall execute
and deliver an appropriate instrument evidencing such release. 
 Upon the merger or consolidation of the Subsidiary Guarantor with or into,
or the dissolution and liquidation of the Subsidiary Guarantor into, a Subsidiary Guarantor or another Person that Guarantees the Securities, the Subsidiary Guarantor shall be released from all obligations under this Supplemental Indenture without
any further action required on the part of the Trustee or any Holder. At the request and expense of the Company, the Trustee shall execute and deliver an appropriate instrument evidencing such release. 
 SECTION 8. Governing Law. This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York but
without giving effect to applicable principles of conflicts of law to the extent that the application of the laws of another jurisdiction would be required thereby. 
 SECTION 9. No Recourse Against Others. A director, officer, employee or stockholder, as such, of the Subsidiary Guarantor shall not have any liability for any obligations of the Company under the Securities or the
Indenture or of the Subsidiary Guarantor under its guaranty, the Indenture or this Supplemental Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a Security, each Holder shall waive
and release all such liability. The waiver and release shall be part of the consideration for the issue of the Securities. 
 SECTION 10.
Multiple Originals. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. One signed copy is enough to prove this Supplemental
Indenture. 
 SECTION 11. Headings. The headings of the Sections of this Supplemental Indenture have been inserted for convenience of
reference only, are not intended to be considered a part hereof and shall not modify or restrict any of the terms or provisions hereof. 
 SECTION 12. Contribution. The Subsidiary Guarantor shall be entitled upon payment in full of all guaranteed Obligations to a contribution from each other Subsidiary Guarantor in an amount equal to such other Subsidiary Guarantor’s pro
rata portion of such payment based on the respective net assets of all the Subsidiary Guarantors at the time of such payment determined in accordance with GAAP. 
  

 51 

 IN WITNESS WHEREOF, the parties have caused this Supplemental Indenture to be duly executed as of the
date first written above. 
  

	
	 [SUBSIDIARY GUARANTOR],

	
	 by
  

	 Name:

	 Title:

	
	LABORATORY CORPORATION OF AMERICA HOLDINGS,
	
	 by
  

	 Name:

	 Title:

	
	 [OTHER SUBSIDIARY GUARANTORS],

	
	 by
  

	 Name:

	 Title:

	
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., Trustee
	
	 by
  

	 Name:

	 Title:

  

 52

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]